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INTRODUCTION 
The 31st Stoneburner Lecture Series was 
planned to present an overview of some important 
aspects of clinical nephrology that we hope are of 
interest to a wide audience. The faculty for this sym-
posium was drawn largely from the Medical College 
of Virginia N ephrology Division, and we were fortu-
nate to have Dr. George E. Schreiner, Professor of 
Medicine at Georgetown University and a long-time 
friend, as our Stoneburner Lecturer. 
Nephrology has grown to a full-fledged specialty 
in only 20 years; knowledge in the field has bur-
geoned, and our understanding of renal diseases has 
changed dramatically in that time. Renal trans-
plantation is now a routine procedure and chronic 
dialysis programs abound. So routine have these 
therapeutic modes become that we may lose sight of 
their costly and awesome social implications. 
The audience attending this lecture series came 
from several states and represented various medical 
disciplines. They entered freely into the discussion 
and thus contributed greatly to the value of the pre-
sentations. We offer thanks to them, to the lecturers 
whose presentations are summarized in this issue of 
the MCV QUARTERLY, and to the Department of 
Continuing Medical Education whose planning for 
this symposium was both thorough and efficient. 
DONALD E. OKEN, M.D. 
Professor of Medicine, and Chairman, 
Division of Nephro/ogy 
Cancer and the Kidney 
DONALD E. OKEN, M.D . 
Professor of Medicine, and Chairman, Division of Nephrology, Medical College of Virginia, Health Sciences 
Division of Virginia Commonwealth University, Richmond, Virginia 
Cancer of the kidney is associated with a bewil-
dering array of extrarenal symptoms, and conversely, 
tumors far removed from the kidney produce in-
triguing renal functional abnormalities. 
A variety of extrarenal complications are seen 
with hypernephromas, most of which rarely accom-
pany Wilms tumors which grow rapidly and generally 
occur before the age of 7. Wilms tumors are quite 
susceptible to radiation therapy and surgery, and are 
to be strongly suspected when hypertension and an 
abdominal mass are found in a small child. Unless 
treated, they rapidly cause death and usually leave 
little opportunity for the patient to develop the strik-
ing extrarenal manifestations seen with hyper-
nephroma. 
Among the fascinating complications of hyper-
nephromas (Table I) is first, the extremely slow 
growth rate of a sizable minority of them. I have seen 
patients known to have hematuria for up to three 
years prior to the time that the tumor was found and, 
on reviewing the intravenous pyelogram done at the 
onset of hematuria, seen evidence that a renal mass 
had been present all along. Those tumors which do 
grow slowly may result in generalized amyloidosis 
both in the kidney and elsewhere. Another peculiarity 
of the hypernephroma, which is almost unique to this 
tumor, is the disappearance of metastases once the 
primary tumor has been removed. In only a few 
instances has there been histologic evidence that the 
"metastatic" lesions were indeed derived from a renal 
cell carcinoma. Nevertheless, the phenomenon of 
spontaneous regression of metastases seems well es-
This paper is supported by USPHS Grant #AM 20132. 
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tablished and offers at least a gleam of hope for those 
in whom pulmonary metastases are found . 
Perhaps equally remarkable is the finding of dis-
tant metastases many years after a renal cell carci-
noma is removed surgically . The longest recorded 
survival between a diagnosis of renal carcinoma and 
the eventual death of a patient whose neoplasm was 
considered inoperable and left in place is 37 years. 1 
Many patients have been reported to develop metas-
tases 5, 10, and even 25 years after the resection of a 
hypernephroma. I have seen a patient who developed 
"solitary" metastases sequentially over a 19-year pe-
riod before he succumbed. Unfortunately, while such 
cases stand out, metastases appear earlier in most 
patients and lead to death within two years in one 
third of patients. 
Renal cell carcinoma also tends to extend via the 
renal vein lumen into the inferior vena cava. Such a 
circumstance is reported to occur in almost 10% of 
patients with hypernephromas,2 and a substantial 
proportion of these tumors extends all the way up the 
vena cava into the right atrium.3 The extending tu-
mor usually is restricted to the venous lumen without 
penetration of the vessel wall and, as a result, is 
generally removable in its entirety. Surprisingly, such 
vascular involvement a lone does not appear greatly 
to alter the prognosis at 5 or I 0 years,4 and extraction 
of the tumor mass is often both possible and desir-
able. 
Fever, unexplained by infection, is a common 
concomitant of hypernephroma. Melicow and Uson& 
have reported that 16% of 577 cases of renal carci-
noma presented with fever, often with weakness, ano-
rexia, and weight loss, without any urologic symp-
toms whatsoever. A much higher percentage 
combined these systemic manifestations with hema-
turia, an abdominal mass, or pain . Thus, it is not 
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TABLE I 
Peculiarities of Hypernephromas 
1. Slow growth frequent 
2. Disappearance of metastases (rare) 
3. Cause of occult fever (FUO) 
4. Renal vein/ vena cava spread 
5. Nonmetastatic hepatic dysfunction 
6. Benign nephrohepatomegaly 
7. Polycythemia, leukemoid reaction , eosinophilia 
8. Heart fai'lure 
9. Spontaneous rupture of kidney 
uncommon for patients with hypernephroma to pres-
ent with "fever of unknown origin" and a baffling 
clinical picture. The fever may be low-grade and con-
stant or intermittent and hectic, temperatures reach-
ing 39.5 C (103 F) and higher. 
First described in 1961,6 a syndrome of non-
metastatic hepatic dysfunction (NHDS) accompanies 
the systemic abnormalities mentioned above in some 
10% of patients with hypernephromas,7 and presents 
with hepatomegaly which differs both functionally 
and histologically from the benign hepatomegaly fre-
quently encountered with such tumors.a Here, bio-
chemical abnormalities include elevated serum alka-
line phosphatase concentrations, hypoalbuminemia, 
and hyperglobulinemia. Liver biopsy may reveal non-
specific inflammatory infiltrates, fatty deposition, de-
generative and regenerative changes of liver cells, and 
areas of focal necrosis.a The syndrome may mimic 
metastatic disease of the liver from which it must be 
distinguished in that it is potentially reversible after 
nephrectomy is performed; recognition of NHDS 
may suggest a diagnosis of previously unrecognized 
hypernephroma. 
Reviews of polycythemia generally include hy-
pernephroma in the list of causes, but in fact, poly-
cythemia has been associated with this tumor in only 
1% to 4% of most reported series. 10 Actually, anemia 
is more the rule than the exception whether or not the 
patient has had significant hematuria. 11 Eosinophilia, 
thrombocytosis, leukocytosis, and even leukomoid 
reactions occur in significant association with hyper-
nephromas.12 Coupled with fever of unknown origin, 
or alone, such findings may present vexing diagnostic 
problems. 
As in many other types of malignancy, throm-
bophlebitis accompanies renal cell carcinoma with 
some frequency. Varicocele, particularly when on the 
right, may be the first clue to the existence of a renal 
tumor. 
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Hypertension is recorded in more than 20% of 
the patients with hypernephroma and in some cases, 
at least, the hypertension has been cured by nephrec-
tomy .5 In others, hypertension is not surgically cor-
rectable, and it is difficult to be sure that the tumor 
was causally related. The renal tumor most clearly 
associated with hypertension is the "juxtaglomerular 
cell" tumor. Neoplastically benign, this growth, orig-
inating in macula densa tissue, produces huge 
amounts of renin with resultant secondary hyper-
aldosteronism and the complications attendant upon 
that condition. It is mentioned here as a rare but 
fascinating renal tumor which produces signs and 
symptoms which may erroneously suggest the exis-
tence of renal arterial stenosis or venous obstruction 
secondary to the spread of renal adenocarcinoma or 
the hyperreninism sometimes associated with Wilms 
tumors.13 
Uncommon but life-threatening vascular com-
plications of hypernephromas include high-output 
congestive heart failure and spontaneous rupture of 
the kidney with hemorrhagic shock. Heart failure is 
attributable to highly vascular metastases with arte-
riovenous communications analogous to those ob-
served in Paget disease. 14 Spontaneous rupture pro-
duces massive retroperitoneal hemorrhage closely 
resembling a ruptured aortic aneurysm and is equally 
lethal. 15 
Renal Complications of Extrarenal Malignancies 
Space does not permit a detailed discussion of 
the many abnormalities of renal function found in 
subjects with malignant diseases; however, I shall 
comment upon the fluid and electrolyte disorders 
which frequently occur (Table 2), and discuss the 
nephrotic syndrome associated with malignancy. 
Hypercalcemia may result from bony metastases 
or the forced immobilization of acutely ill patients. 
Certain cases are the result of parathormone secreting 
tumors which function autonomously, 16 and a grow-
ing number of reports have called attention to the 
existence of prostaglandin-secreting tumors produc-
ing hypercalcemia which may be reversed with indo-
methacin.17 The hypercalcemia caused by both hor-
mone-secreting tumors is reversible with complete 
removal of the tumor. Persistence of hypercalcemia 
after the primary tumor is excised may reflect the 
other causes of hypercalcemia (see Table 2 ), or be the 
result of metastases which, like the parent tumor, also 
synthesize prostaglandins or parathormone. 
Hypercalcemia, if severe, may have devastating 
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TABLE 2 
Electrolyte Abnormalities with Nonrenal Malignancies 
I. HYPERCALCEMIA-producing severe volume depletion and functional renal failure , nephrolithiasis or nephrocalcinosis: 
a. Metastases 
b. Corticosteroid withdrawal/adrenal insufficiency 
c. Prostaglandin-secreting tumors 
d. Forced immobilization 
e. Parathormone-secreting tumors 
2. VOLUME DEPLETION AND HYPONATREMIA •-producing functional renal failure: 
a . Hypoadrenalcorticism of tumor replacement, amyloidosis, surgical ablation of the adrenals, disseminated intra vascular coagulation 
(DIC). 
b. Excessive diuretic therapy for peritoneal metastases or mechanical edema. 
c. Rapidly developing ascites and edema 
d. Extrarehal electrolyte losses:secretory diarrheas, villous adenomas , drug Rx hyperemesis, intestinal obstruction, malabsorption and 
carcinoid. 
•To be distinguished from the syndrome of inappropriate ADH secretion (CNS tumor/ metastases, vasopressin-secreting tumors, 
vincristine/ cyclophosphamide therapy, and tricyclic anticonvulsants) where renal function does not specifically become impaired. 
3. VOLUME DEPLETION AND HYPERNATREMIA-with functional renal failure: 
a. Diabetes insipidus of pituitary replacement, brain metastases, urinary outflow obstruction. 
b. Impaired thirst mechanism-organic or functional results of cachectic illness. 
c. Kaliopenic and hypercalcemic nephropathy 
d . Nasogastric feeding-osmotic diuresis 
4. KALIOPENIC NEPHROPATHY-with impaired concentrating capacity and susceptibility to pyelonephritis: 
a. Pernicious gastrointestinal electrolyte loss (see section 2) 
b. " ACTH"-producing tumors 
c. Juxtaglomerular cell tumors 
d. Improper diuretic therapy 
e. Lysozymuric and nonlysozymuric leukemias 
effects upon the kidney, producing severe volume 
depletion and functional renal failure, nephrolithiasis 
with infection and urinary outflow obstruction, or 
severe tubulointerstitial disease due to nephrocalci-
nos1s. 
Volume depletion and hyponatremia are fre-
quent complications which plague the patient with 
malignant disease. Generically, the concurrence of 
volume depletion and hyponatremia reflects a state in 
which both sodium and water are lost from the body 
in large amounts but the net sodium loss exceeds the 
water deficit. Causes include adrenal insufficiency 
owing to tumor replacement, adrenal amyloidosis, 
surgical ablation of the adrenals as a therapeutic 
adjuvant, and disseminated intravascular coagu-
lation. Ill-advised sodium restriction with vigorous 
diuretic therapy in an attempt to minimize mechani-
cal edema or ascites due to peritoneal metastases is a 
reasonably common cause of hyponatremic volume 
depletion. The rapid development of ascites and 
edema in sodium-restricted patients is another cause. 
Massive electrolyte losses may occur through the in-
testinal tract as a result of the hyperemesis associated 
with cancer chemotherapy, the secretory diarrheas 
[amine precursor uptake and decarboxylation 
(APUD) syndromes], mucus-secreting intestinal 
tumors, intestinal obstruction, or malabsorption. 
Massive fluid losses may be seen in the carcinoid 
syndrome. The severe volume depletion .attendant 
upon these complications may produce major abnor-
malities in renal function unless corrected. 
Hyponatremia may also be seen in the presence 
of extracellular fluid volume expansion-the so-
called syndrome of inappropriate antidiuretic hor-
mone (ADH) secretion. Causes include vasopressin-
secreting tumors (especially of lung), primary or 
metastatic intracranial malignancies, vincristine or 
cyclophosphamide therapy to retard tumor growth, 
and ~he tricyclic anticonvulsants .18 
Volume depletion may coexist with hyper-
natremia for a variety of reasons. Diabetes insipidus 
may result from tumor invasion of the pituitary 
gland, intracranial metastases, or urinary outflow ob-
struction. Nasogastric feeding of concentrated solu-
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tions lacking in free water is a common cause of an 
obligatory solute diuresis. Impaired thirst due to ei-
ther organic brain disease or as a functional result of 
a cachectic illness may contribute greatly to the devel-
opment of hypernatremic volume depletion, a situa-
tion which is further aggravated if kaliopenic or hy-
percalcemic nephropathy is present. 
Kaliopenic (hypokalemic) nephropathy is mani-
fested by impaired concentrating capacity and an 
increased susceptibility to pyelonephritis. It may re-
sult from pernicious gastrointestinal electrolyte 
losses, hyperadrenal corticism secondary to an ad-
renocorticotropic hormone (ACTH)-producing tu-
mor, juxtaglomerular cell tumors, or improper diu-
retic management. Major degrees of hypokalemia 
may be seen in patients with leukemia, especially 
those leukemias associated with lysozymuria. 19 Im-
paired concentrating capacity may well lead to seri-
ous volume depletion and secondary renal dysfunc-
tion. 
Nonelectrolyte-related abnormalities of the uri-
nary tract are listed in Table 3, but cannot be covered 
in detail in this brief review. 
Nephrotic Syndrome Associated with Malignancy 
An increasing number of reports amply docu-
ment the association of the nephrotic syndrome with 
TABLE 3 
Nonelectrolyte Renal Complications of Malignancies 
I. Fanconi syndrome 
2. Renal tubular acidosis 
3. Hydronephrosis-obstructive renal failure 
4. Renal amyloidosis 
5. Urate nephropathy 
6. Radiation nephritis 
7. "Citrovorum rescue," antimetabolite nephropathy 
8. Myeloma kidney 
9. Renal hemorrhage, outflow obstruction 
JO. Cortical necrosis post-disseminated intravascular coag-
ulation (DIC) 
11 . Tumor-related lupus erythematosus (especially with 
lymphoma ) 
12. Renal vein/ arterial or vena caval occlusion 
13. Vasomotor nephropathy-hemorrhage, sepsis, shock, 
and so forth 
14. Nephrolithiasis/ nephrocalcinosis 
15. Obstruction of bladder outflow, ureters, or urethra by 
tumor invasion 
16. Renal invasion by metastases 
17. Benign nephromegaly, etiology unknown 
18. Retroperitoneal fibrosis/ tumor invasion, producing 
ureteral obstruction 
19. Nephrotic syndrome 
20. Acute papillary necrosis, pyelonephritis 
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malignant tumors.20 Some cases are the result of 
amyloidosis, others to renal venous outflow obstruc-
tion, and still others to probable immune mecha-
nisms. Myeloma and lymphoproliferative disorders are 
among the most common tumor-related causes of 
amyloidosis, yet solid tumors also may cause amyloid 
deposition if their course is not an accelerated one.22 
Invasion of the renal veins and vena cava by hyper-
nephromas or other tumors, and compression of 
venous structures by retroperitoneal nodes, tumor 
mass, or retroperitoneal fibrosis may produce me-
chanical edema and marked proteinuria but are un-
common causes of the nephrotic syndrome. 
Tumor-related nephrotic syndrome occurs with 
some frequency in the absence of either amyloidosis 
or venous obstruction, Hodgkin disease leading the 
list of causes.21 Lymphosarcoma, chronic lymphocy-
tic leukemia, and Burkitt lymphoma also have been 
associated with frank nephrosis.21 Of the solid tu-
mors, bronchogenic carcinoma has been the most 
often found. Malignancies of the stomach, colon, 
breast, skin, ovary, oropharynx, and kidneys have 
all been incriminated. 
The majority of lymphoma-related cases have 
shown minimal glomerular changes on biopsy or 
postmortem study. Most other types of tumors have 
produced membranous, proliferative or mixed mem-
branous and proliferative lesions. Reversal of the 
nephrotic syndrome after excision or chemotherapy 
of the primary tumor has been observed by many 
authors, the return of proteinuria signaling regrowth 
of the malignancy 21 
In this overview, I have tried to touch on the 
highly complex interaction between carcinomatosis 
and the kidney. The manifestations of this relation-
ship are so diverse and numerous that it is well to 
remember the adage, "Many a medical reputation 
has been lost in the retroperitoneum." It is hoped 
that continued awareness of the protean manifesta-
tions of tumors relating to the kidney will help to 
preserve the reputations of all clinicians. 
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Glomerulonephritis 
WILLIAM F . FALLS, JR., M .D. 
Medical Service, Veterans Administration Hospital, and Department of Medicine, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
In this paper the histologic picture of the most 
common disorders usually classified under the head-
ing of glomerulonephritis will be reviewed, and the 
subject of angiitis will be briefly addressed. A special 
effort will be made to relate renal biopsy findings to 
the immunologically mediated pathogenetic process 
which is thought to be operative in each case. Where 
it seems appropriate, a few comments will also be 
made on clinical and pathological correlations. The 
specific entities to be covered include: diffuse prolifer-
ative glomerulonephritis; focal proliferative glomeru-
lonephritis; membranous glomerulonephritis; anti-
basement membrane antibody disease; rapidly 
progressive glomerulonephritis ( crescentic disease); 
membranoproliferative glomerulonephritis; lipoid 
nephrosis (nil disease); focal, segmental, and global 
sclerosis; polyarteritis nodosa; hypersensitivity angi-
itis; and Wegener granulomatosis . Few comments 
will be made about therapy because that subject is 
covered elsewhere in this issue. The review will be 
concluded by a discussion of the prognostic value of 
information gleaned from careful biopsy evaluation. 
Two types of immunologic injury to the kidney 
have been clearly defined in experimental models and 
are thought to have distinct clinical counterparts.1 
These are immune-complex mediated disease and 
antibasement membrane antibody disease. The 
former is the most common and will be considered 
first. 
Immune-Complex Glomerulonephritis 
The pathogenesis of several glomerulonephritic 
patterns to be discussed subsequently seems to be of 
Correspondence and reprint requests to Dr. William F. Falls, 
Jr., Renal Section, VA Hospital, Richmond, VA 23249. 
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this type. In the classic immune-complex model, the 
following sequence of events is thought to occur: an 
antigenic substance gains access to the bloodstream 
and is delivered to immunologically competent cells 
which begin making antibody in response to the chal-
lenge; as antibody is released into the circulation, it 
combines with antigen to form complexes. Under 
certain circumstances of antigen excess, the com-
plexes which are formed are small and soluble and 
are not phagocytized in the reticuloendothelial sys-
tem; these activate the complement cascade via the 
classic pathway (C1 ___, C4 ___, C2 ___, C3 ), and the entire 
aggregate of antigen, antibody, and complement 
components precipitates in the region of the glomeru-
lar basement membrane. The terminal components of 
the complement system include substances which in-
crease vascular permeability and are leukotactic. An 
increase in the permeability of the capillary wall leads 
to leakage of protein into Bowman space and the 
influx of leukocytes may cause proteolytic destruc-
tion of portions of the glomerular capillary wall; in 
response to this assault, endothelial and mesangial 
cell proliferation occur. Thus, any antigen capable of 
stimulating an antibody response is a potential cause 
of immune-complex mediated injury. As we shall see, 
numerous inciting antigens have been identified, but 
the pattern of injury may vary considerably, probably 
depending on the nature of the antigen and the re-
sponsiveness of the host.2 
Our understanding of the nature of immunologic 
injury to the glomerular capillary has been enhanced 
greatly by the development of immunofluorescent 
staining techniques. In this process a quick-frozen 
renal biopsy section is treated with a fluorescent-
tagged antibody against a specific class of human 
globulin, complement component, or fibrinogen. 
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Fig 1-Immunofluorescent microscopic preparation (anti-IgG) of 
a portion of a glomerulus from a patient with poststreptococcal 
glomerulonephritis. Note "lumpy-bumpy" pattern. (X 1500). 
When this preparation is viewed with fluorescent mi-
croscopy, a clear picture of the area of protein depo-
sition is obtained. In the case of immune-complex 
mediated disease, a "lumpy-bumpy" pattern will be 
observed and is the hallmark of this type of injury. 
Diffuse Proliferative Glomerulonephritis 
Figure 1 is a photomicrograph of the im-
m unofluorescent staining for lgG in a patient with 
acute poststreptococcal glomerulonephritis. Note the 
coarse, granular deposition of the immuno-
fluorescent material in the area of the capillary base-
ment membrane and the mesangium. Figure 2 is the 
light microscopic correlate of this lesion and shows 
the characteristic picture of diffuse, proliferative glo-
merulonephritis. The glomerulus is swollen and the 
capillary loops are occluded by proliferating mesan-
gial and endothelial cells; there is marked hyper-
cellularity and an influx of foreign inflammatory cells 
is noted . Figure 3 is a high-power view of an electron 
micrograph which demonstrates the classjc appear-
ance and location of the electron-dense deposits 
which are thought to represent the deposited com-
plexes. Note that the deposits are quite large, "hump-
like," and located in a subepithelial position; the foot 
processes in the area of the deposit have become 
fused. This phenomenon of foot process fusion has 
been found to correlate closely with the presence of 
proteinuria. 
The immunofluorescent and light microscopic 
picture described above is typical of the aggressive 
type of immune-complex mediated disease character-
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Fig 2-Light microscopic preparation (H & E) of a portion of 
renal biopsy from a patient with diffuse proliferative glomerulone-
phritis following streptococcal infection (X200). 
ized by poststreptococcal glomerulonephritis but is 
by no means specific to it. A similar light micro-
scopic appearance may be seen in some patients with 
lupus erythematosus, bacterial endocarditis, nephritis 
associated with infected ventriculojugular shunts, 
cryoglobulinemic nephropathy, and other antigenic 
insults. 2 Diffuse proliferative glomerulonephritis sec-
ondary to lupus erythematosus can usually be distin-
guished from poststreptococcal disease because the 
electron-dense deposits in lupus are usually located 
on the subendothelial surface of the basement mem-
brane (Fig 4) and discrete viruslike particles may also 
be evident.2 The site of deposition in other diseases is 
Fig 3-Electron microscopic preparation of a portion of a glomer-
ulus from a patient with acute poststreptococcal glomerulonephri-
tis . Note large subepithelial electron-dense deposit, "hump" (X 
32,000). 
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Fig 4-Electron microscopic preparation of a portion of a glomer-
ulus from a patient with systemic I up us erythematosus and a 
diffuse proliferative lesion by light microscopy. Note large sub-
endothelial deposits (X 10,000). 
variable, but in many cases with proliferative lesions 
they are subendothelial. 
In most cases of diffuse proliferative glomerulo-
nephritis associated with lupus, one can find serologic 
evidence of activation of the classic complement 
pathway (low serum C 1q _, C2 _, C4 _, Cs).2 Such 
changes are variable in other diseases with prolifera-
tive lesions and in some cases of poststreptococcal 
disease there may also be evidence of activation of the 
alternate complement pathway. In this circumstance 
Cs is activated directly, bypassing the earlier com-
ponents. A number of substances are known to acti-
Fig 5-Light microscopic preparation (H & E) of a portion of a 
renal biopsy from a patient with systemic lupus erythematosus, 
showing a focal proliferative lesion (X 400). 
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Fig 6-Red blood cell cast in urine sediment from a patient with 
poststreptococcal glomerulonephritis (X 1,000). 
vate Cs directly. These include endotoxin, properdin, 
and IgA-containing complexes. 
The course of immune-complex mediated prolif-
erative glomerulonephritis is highly variable, depend-
ing on the disease process, and may well be related to 
the supply of antigen. In lupus erythematosus there is 
an inexhaustible supply of antigen in the form of 
various nucleoprotein derivatives including double-
stranded DNA.s As a consequence, lupus glomerulo-
nephritis tends to be an ongoing, progressive disease. 
On the other hand, poststreptococcal disease tends to 
be self-limited, particularly in children,4 perhaps be-
cause of the rapid eradication of antigen from the 
body. 
Focal Proliferative Glomerulonephritis 
Another histologic pattern of immune-complex 
mediated glomerular injury is demonstrated in Figure 
5. This is the pattern of focal (among glomeruli) and 
segmental (within a glomerulus) glomerulonephritis. 
By immunofiuorescence the deposited globulins tend 
to be localized more within the mesangial region than 
along the capillary walls, and IgA may frequently be 
found along with other immune globulins and com-
plement components. Evidence of alternate com-
plement pathway activity may also be seen and it has 
been suggested that IgA-containing complexes may 
set this pathway in motion.5 
Focal proliferative lesions may be seen in a wide 
variety of disorders including some patients with 
lupus erythematosus, Schonlein-Henoch purpura, 
and Berger disease (IgA nephropathy).2 
Figure 6 is the photomicrograph of a red cell 
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Fig 7-Light microscopic preparation (PAS) of a portion of a 
glomerulus from a patient with membranous glomerulonephritis 
( X 200). 
cast. This structure is considered to be characteristic 
of inflammatory or necrotizing disease of the glomer-
ulus. It is introduced at this time because, being the 
most characteristic feature of the urine sediment in 
patients with glomerulonephritis, it tends to correlate 
with the type of proliferative lesions which have just 
been described. 
Membranous Glomerulonephritis 
In each of the immune-complex mediated dis-
orders mentioned above, the light microscopic pic-
ture demonstrated evidence of cellular proliferation 
Fig 8- Light microscopic preparation (H & E) from renal biopsy 
of a patient with rapidly progressive glomerulonephritis. Note 
marked crescent formation by proliferating glomerular epithelial 
cells (X 80). 
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Fig 9-Immunoftuorescent preparation (IgG) from a portion of 
biopsy of a patient with anti basement membrane antibody disease. 
Note linear pattern of fluorescence. (X 1500). 
and inflammation. Such is ordinarily not the case in 
membranous glomerulonephritis. Figure 7 demon-
strates the typical light microscopic picture of this 
lesion. The only recognizable abnormality is thick-
ening of the basement membrane. On immuno-
fluorescent and electron microscopic study this mem-
brane alteration is found to be secondary to finely 
granular deposition of immunoprotein along the sub-
epithelial border of the basement membrane. In addi-
tion to IgG and IgM, complement components may 
be deposited. Why this deposition is not associated 
with the induction of an inflammatory reaction like 
that described above is unclear. In animal models 
similar lesions are associated with small, weak-affin-
ity antibodies6 and it is possible that this is also true 
in human disease. 
A membranous pattern may be seen in a number 
of clinical states including: lupus erythematosus, drug 
intoxication (heavy metals, tridione, penicillamine ), 
solid tumors (carcinoma of the lung and colon), 
sickle cell disease, hepatitis B infection, and as an 
idiopathic occurrence.2 Patients with membranous 
nephropathy usually present with a nephrotic state 
characterized by edema, hypoalbuminemia, hyper-
cholesterolemia, heavy proteinuria, and fat-filled 
macrophages in the urine sediment. 
Antibasement Membrane Antibody Disease 
The second, well-established type of injury to the 
glomerular capillary is that caused by circulating 
antibasement membrane antibody. 1 In this disorder 
antibodies, usually of the IgG class, develop against 
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Fig IO-Electron microscopic representation of basement mem-
brane reduplication in a patient with type I membranoproliferative 
glomerulonephritis. (X 14,000). 
some antigenic component of the basement mem-
brane. These abnormal antibodies enter the circula-
tion and are carried to the kidney where they attach 
to antigens on the basement membrane. This reaction 
of antigen and antibody activates the complement 
cascade, probably via the classic pathway, and in-
duces an inflammatory reaction in a manner analo-
gous to that described earlier. Under certain cir-
cumstances there may be cross-reactivity of the 
glomerular antibasement membrane antibody with 
other basement membranes in the body, particularly 
the lung. It is this sharing of antigenic determinants 
that is thought to lead to lung hemorrhage and glo-
merulonephritis in Goodpasture syndrome.7 
Rapidly Progressive Glomerulonephritis ( Crescentic 
Disease) 
A histologic picture of marked proliferation of 
both visceral and parietal epithelial cells, leading to 
extensive crescent formation (Fig 8) associated with a 
rapidly progressive, downhill clinical course may be 
seen under a number of different clinical circum-
stances.8 It is classically seen in the kidneys of pa-
tients with Goodpasture syndrome and in this setting 
immunofluorescent staining invariably shows a linear 
deposition of antibody (Fig 9). A crescentic pattern 
may also be seen in patients with rapidly progressive 
glomerulonephritis without lung hemorrhage. In this 
circumstance only about 40% of the patients show an 
immunofluorescent pattern which is indicative of 
antibasement membrane antibody disease.2 The re-
mainder show a "lumpy-bumpy" fluorescent pattern 
indicative of an immune-complex pathogenesis. This 
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Fig I I-Electron micrograph from a patient with membranopro-
liferative glomerulonephritis type II . Note the homogeneous elec-
tron-dense deposit throughout the basement membrane. (X 
15,000). 
is confirmed by electron microscopy which demon-
strates electron-dense deposits. The common de-
nominator of the crescentic pattern seems to be dam-
age to the glomerular basement membrane of such a 
magnitude that fibrinogen and other components 
leak into Bowman space where the coagulation proc-
ess is activated. This , in turn, stimulates proliferation 
of epithelial cells and attracts an influx of macro-
phages.9 The picture of crescent formation and im-
mune-complex deposition may also be seen in diffuse 
proliferative lupus and certain of the angiitic proc-
esses to be discussed later . 
Glomerulonephritis in Which the Pathogenesis is Not 
Clearly Defined: Membranoproliferative (Mesan-
giosclerotic Glomerulonephritis) 
Great interest is currently being focused on le-
sions included under this heading10; its classification 
is in a state of almost daily flux. On light microscopy 
the glomeruli from patients with this type of lesion 
show a lobular pattern which is associated with an 
increase in both the cellular and acellular com-
ponents of the mesangium. This type of lesion may be 
seen in a variety of disease states including lupus 
erythematosus and non-resolving poststreptococcal 
glomerulonephritis. It is nonspecific in and of itself. 
Typical membranoproliferative lesions have also 
been described in children and adolescents who usu-
ally present with a nephrotic syndrome accompanied 
by varying numbers of red blood cells and red blood 
cell casts in the urine sediment. Early on, attention 
was drawn to the fact that many of these children had 
low levels of circulating C3 and some had evidence of 
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Fig 12-Electron microscopic preparation of a portion of a renal 
biopsy from a patient with "nil disease." Note normal-appearing 
basement membrane, the absence of deposits, and the presence of 
fused foot processes (X 14,000). 
activation of the alternate complement pathway as 
manifested by the presence of properdin in the glo-
merular mesangium .2 Careful evaluation of biopsies 
with silver staining techniques revealed extensive 
reduplication of the basement membrane. Electron 
microscopic study confirmed this finding and sug-
gested that the new basement membrane was laid 
down by proliferating mesangial cells burrowing be-
neath the cytoplasm of the endothelial cells (Fig IO). 
Subsequent evaluation of a larger number of cases 
has revealed the presence of some lgG deposits and 
early-reactive complement components in the mesan-
gium. These patients have been classified as having 
membranoproliferative glomerulonephritis, type I 
Fig 13-Light microscopic representation (PAS) of renal biopsy 
section from a patient with focal , segmental sclerosis. Note the 
peripheral hyaline lesions in lower glomerulus while upper glomer-
ulus is relatively spared. (X 200). 
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Fig 14-Light microscopic view of necrotic glomerulus (H & E) 
from a patient with Wegener granulomatosus. (X 500). 
and are thought to have a variant of a classic im-
mune-complex mediated disease. At present there is 
no clue as to the nature of the inciting antigen or 
antigens. 
Membranoproliferative glomerulonephritis, type 
II, on the other hand, seems to be a more specific, 
homogeneous disease entity, albeit poorly under-
stood. This disorder is also seen more frequently in 
younger individuals who usually present with a neph-
rotic syndrome. The light-microscopic biopsy picture 
is indistinguishable from the lobular pattern with 
basement membrane reduplication seen in type I. A 
distinctive dense deposition involving all of the base-
ment membranes is seen with electron microscopy 
(Fig 11 ), 10 however, and positive immunofluorescent 
staining is seen only for complement. The staining is 
intense and seems to involve the same areas as the 
electron-dense deposits. These abnormal histologic 
changes accompany a blood chemical picture which 
is characterized by low Ca levels, normal early-react-
ing complement components, and the presence of an 
abnormal circulating globulin component which is 
capable of activating Ca directly (Ca nephritic factor). 
Type II membranoproliferative glomerular 
nephritis is felt to be mediated via alternate pathway 
complement activation alone. For reasons that are 
not clear, type II disease has been observed with some 
frequency in patients with partial lipodystrophy and 
glomerulonephritis. Both type I and type II may 
show recurrence in the transplanted kidney. 
Lipoid Nephrosis of Childhood (Nil Disease) 
Most young children who have a nephrotic syn-
drome display no recognizable abnormality on light 
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or immunofluorescent microscopy of their renal 
biopsy. The only recognizable change is fusion of the 
epithelial cell foot processes (Fig 12) which can be 
observed on electron microscopic section. This histo-
logic pattern correlates with an essentially normal 
urine sediment. If cellular elements are present in 
more than very scant numbers, some other process 
must be considered. A similar lesion has been noted 
to occur in some patients with active Hodgkin disease 
and to disappear with successful treatment of the 
underlying disorder. This observation, taken in con-
junction with the recognition that Hodgkin disease is 
a T-cell related malignancy, has invited speculation 
that the idiopathic nephrotic syndrome of childhood 
may also be a manifestation of abnormal T-cell func-
tion.11 Such conjecture is interesting but entirely un-
proven. 
Focal, Segmental, Global Sclerosis 
Those young children with a nephrotic syn-
drome who have neither a spontaneous remission nor 
a favorable response to steroid therapy probably 
have this disorder. In most cases the initial in-
volvement is deep in the juxtamedullary glomeruli, 
and centrifugal progression occurs throughout the 
entire cortex. In the focal lesion, some glomeruli are 
involved by segmental areas of mesangial sclerosis or 
hyalinization which are easily noted on light micros-
copy (Fig 13). Immunofluorescent studies may show 
spotty, nonspecific staining for IgG and complement, 
and electronmicroscopy demonstrates an increase in 
mesangial matrix material with an occasional mesan-
gial deposit. In patients with global sclerosis the 
changes are similar but involve the entire glomerulus. 
The etiology of this disorder is uncertain, but an 
immune-complex mechanism is suggested by the 
finding of immunoglobulins in the sclerotic lesions 
and its occurrence in association with hepatitis B 
infection.12 
Angiitis 
The angiitic processes are probably immunologi-
cally induced and for our purposes may be divided 
into three groups, depending on the size of vessels 
involved and the presence or absence of gran-
ulomatous change. 
Polyarteritis nodosa: Histologically this disorder 
is characterized by necrotizing, inflammatory lesions 
of medium-sized and large arteries. The hallmark of 
this process in the kidney is the presence of ischemic 
necrosis and infarction. Deposits of immune globu-
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fin, complement, and fibrin may be seen with immu-
nofluorescent stains of the vessel walls. Clinically, 
patients with this disturbance present with a picture 
of hypertension, mononeuritis multiplex, central ner-
vous system disturbances, and progressive renal in-
sufficiency with an active urinary sediment. 
Hypersensitivity angiitis: This is an angiitic proc-
ess which involves small vessels including arterioles, 
venules, and the capillary loops of the glomerulus. 
Segmental necrosis of glomerular tufts may be seen 
on light microscopy and there may be nonspecific 
deposition of immune globulin and complement 
noted by immunofluorescence and light microscopic 
studies. Vasculitis of the skin is a frequent accom-
paniment of the renal lesions. This type of angiitis has 
been reported as a manifestation of hypersensitivity 
to a number of drugs. Hepatitis B infection has also 
been described in association with this disorder. 13 
Granulomatus arteritis: Wegener granulo-
matosis, the prototype of this disturbance, is charac-
terized by the presence of necrotizing granulomas in 
the respiratory tract and a necrotizing, proliferative 
lesion of the renal glomerulus (Fig 14). Immunoglob-
ulins and fibrin are deposited in a nonspecific glo-
merular pattern and crescents may be seen with fre-
quency. Although thought to be of immunologic 
origin , the antigenic stimulus for this disease is un-
known.14 
Prognosis of Immunologically Mediated Renal Injury 
The question, Why do a biopsy? frequently 
arises. Information from tissue examination should 
be of value in determining the proper diagnosis, prog-
nosis, and treatment. We have pointed out the diag-
nostic value in the histologic review above. The prog-
nostic information to be gained may be substantial 
and is outlined below. 
As noted earlier, the course of a patient with an 
immune-complex mediated diffuse proliferative le-
sion is variable and relates to the underlying disease 
process . In those patients with an idiopathic lesion or 
in lupus the prognosis is usually poor. Patients with 
membranous lesions secondary to a recognized anti-
gen which can be withdrawn or eradicated frequently 
show remission or improvement. Thirty percent of 
patients with an idiopathic nephrotic syndrome sec-
ondary to membranous nephropathy may have a 
spontaneous remission whereas the course of the re-
mainder tends to be indolently downhill with a con-
tinued nephrotic syndrome. Patients with crescentic 
disease either related to an antibasement membrane 
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antibody or to circulating immune complexes do 
poorly. The prognosis in both types of membrano-
proliferative lesions is one of slow progression to end-
stage disease in 10-12 years. The prognosis in nil 
disease is excellent with a high incidence of spontane-
ous remissions. Focal and global sclerotic lesions are 
associated with a slow but inexorable deterioration in 
renal function. The prognosis for untreated poly-
arteritis nodosa and Wegener granulomatosis is very 
poor. A similar prognosis is seen with small vessel 
angiitis unless it is drug-related in which case with-
drawal of the offending agent may be accompanied 
by improvement. 
In summary, the histopathology of the more 
common glomerulonephritic and angiitic lesions 
which may be seen on renal biopsy has been re-
viewed. Their diagnostic and prognostic implications 
have been discussed. Undoubtedly, the future will 
bring alterations in the presently outlined classifica-
tions as our understanding of the underlying imm u-
nologic pathogenetic mechanisms expands. 
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Management of the Nephrotic Syndrome 
DOUGLAS M. LANDWEHR, M.D., PH.D. 
Associate Professor of Medicine, Division of Nephro/ogy, and Director, Hemodialysis Unit, Medical College of 
Virginia, Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
The nephrotic syndrome represents one of the 
major clinical problems in nephrology. It is usually 
defined as the constellation of clinical findings which 
includes edema, massive proteinuria, low serum albu-
min, high serum cholesterol, and the presence of oval 
fat bodies in the urine.1 However, if we focus on the 
primary disturbance in the patient, that is, massive 
proteinuria, the nephrotic syndrome may be defined 
more simply as the clinical and metabolic con-
sequences of persistent and massive proteinuria. The 
other manifestations listed in the classic definition are 
all inconstant and secondary to this loss of protein 
and may be found in other clinical disorders. Protein-
uria is considered massive when it is greater than 3 .5 
mg/ kg body weight per day, and persistent when 
present for many weeks or months. For diagnosis of 
the nephrotic syndrome, 24-hour urine protein excre-
tion must be measured; a spot measurement is in-
adequate because some patients with massive pro-
teinuria produce occasional specimens with little or 
no protein. 
In understanding potential causes of the neph-
rotic syndrome, it is useful to recognize two general 
categories of disease.2 •3 One is the nephrotic syn-
drome associated with systemic illnesses. The other is 
not associated with a recognizable systemic process, 
and thus reflects only intrinsic renal disease. The 
most common systemic diseases associated with the 
nephrotic syndrome are diabetes mellitus, systemic 
lupus erythematosus, malignancy and amyloidosis. 
Additionally, there is a large variety of other diseases 
less commonly associated with the nephrotic syn-
Correspondence and reprint requests to Dr. Douglas M. 
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drome. Many of these involve immune and toxic 
reactions related to drugs, as well as infectious and 
environmental agents. Although these entities are un-
common, it is important to recognize them, as re-
moval of the dn1g or toxin, or definitive treatment of 
the infection, is a fundamental part of the manage-
ment of these patients. Drugs shown to be associated 
with the nephrotic syndrome include the antiepileptic 
drugs paradione and tridione, anticoagulant agents, 
and penicillin. Forms of allergic reactions associated 
with the nephrotic syndrome include those following 
bee sting or exposure to poison oak or poison ivy. 
Chronic infections which are known to be com-
plicated by the nephrotic syndrome include syphilis, 
malaria, hepatitis and toxoplasmosis. 
There are several intrinsic renal diseases which 
cause the nephrotic syndrome. Recognition of these 
depends on characteristic morphologic findings in the 
renal biopsy specimen. The first is the clini-
copathologic entity referred to as nil disease or lipoid 
nephrosis .2 As implied in the term nil disease, there is 
little, if any, change in the normal architecture of the 
kidney when examined by light microscopy; however, 
electron microscopy does disclose changes of epithe-
lial foot process fusion. Nil disease is the pre-
dominant cause of the nephrotic syndrome in chil-
dren, particularly between ages 2 and 5 years; it is a 
less common cause in adults, accounting for approxi-
mately 15% of adult cases of primary nephrotic syn-
drome. 
The second intrinsic renal disease which causes 
the nephrotic syndrome is a condition termed idiopa-
thic membranous glomerulopathy2 and it is found 
most frequently in adults . This term refers to the 
morphological changes of diffuse thickening of the 
basement membrane of all glomeruli. Within and to 
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the outside of the basement membrane are found 
desposits which have been shown to contain immu-
noglobulins and serum complement components. 
They are thought to result from the deposition of 
circulating complexes of antigen and antibody, and 
are responsible for injury to the glomerulus which 
results in heavy proteinuria. Membranous glomeru-
lopathy accounts for approximately 40% of the pri-
mary nephrotic syndrome in adults . It is relatively 
uncommon in children in the United States. 
A third intrinsic renal disease which causes 
nephrotic syndrome is termed membranoprolifera-
tive glomerulonephritis.3 In this disease the mesangial 
or supporting cell of the glomerulus is affected. Al-
though the cause of this disease is not understood, 
immune deposits may be found in the mesangial area. 
This is an uncommon cause ofnephrotic syndrome in 
adults but is perhaps the most common cause in 
patients aged I 0 to 20 years. Prognosis for this dis-
ease is not good as its course commonly leads to 
renal failure . 
The fourth intrinsic disease recognized as caus-
ing the nephrotic syndrome is termed focal sclerosing 
glomerulonephritis.2•3 As this pathologic term in-
dicates, the lesion involves a process which at first is 
confined only to parts of individual glomeruli. Again, 
the cause is unknown, although immune deposits are 
found in the areas of scarring. Like membranoprolif-
erative glomerulonephritis, this disease also fre-
quently results in renal failure. 
In managing patients with the nephrotic syn-
drome, it is useful to bear in mind the patho-
physiology of the syndrome. Although the most fre-
quent concern is with the development of massive 
edema, it should be remembered that such edema is a 
consequence of massive loss of protein into the urine. 
This in turn leads to depletion of intra vascular albu-
min and reduction of plasma oncotic pressure. In 
turn, fluid escapes from the vascular compartment 
into the interstitial tissue. As a compensatory re-
sponse to the fall in plasma volume, there is de-
creased salt and water excretion by the kidney which 
may further increase the accumulation of edema. If 
intravascular albumin depletion can be prevented or 
reversed, significant problems with edema and fluid 
retention will not develop. As albumin depletion is 
caused primarily by loss through a leaky glomerulus, 
the first approach, if possible, should be to reverse the 
albumin leak . As we shall see later, this is regularly 
accomplished only in nil disease in which the leak is 
predictably corrected by steroids. In other conditions 
in which the albumin leak is not remedial, metabolic 
considerations should be first and foremost in man-
agement. A high-protein and high-caloric diet can 
result in significant repletion of intravascular albu-
min.5 To the extent that albumin loss can not be 
matched by increased dietary protein, then salt re-
striction and diuretics may be necessary to prevent 
undue accumulation of edema. From a practical 
standpoint, the diet of the nonazotemic patient 
should contain a minimum of 100 gm of high-quality 
protein and approximately 3,500 calories for the av-
erage nephrotic adult. At times, protein intake of 2-3 
gm / kg of body weight will be required. Since many of 
these patients are anorectic and have been grossly 
malnourished for some time, the diet may have to be 
increased gradually until these goals are accom-
plished. This will require persistent and close cooper-
ation between the patient, the physician, and the 
dietitian . 
If serum albumin remains severely depressed de-
spite optimal intake of protein, it is probable that salt 
and water restriction, as well as diuretics, may be 
necessary for control of severe edema. One must re-
member that, although there may be massive accu-
mulation of edema, there is at the same time potential 
for significant intravascular volume depletion. Ther-
apy designed to reduce edema accumulation may fur-
ther reduce intravascular volume, and potentially re-
sult in shock. Judicious use of salt restriction and 
diuretics is necessary in order to achieve the appro-
priate balance in which severe accumulation of 
edema is prevented without unduly jeopardizing in-
travascular volume. In general, this involves sodium 
restriction of approximately 40-60 mEq/p day. Di-
uretics should be adjusted so that edema is not re-
duced to the point where postural changes in blood 
pressure and pulse occur. Although this may involve 
some trial and error, one can usually arrive at a body 
weight in which massive edema is prevented but not 
at the expense of severe volume depletion. 
The nephrotic syndrome may also be com-
plicated by increased susceptibility to infection. Prior 
to the introduction of steroid and antibiotic therapy, 
pneumococcal pneumonia and/or peritonitis was a 
major cause of death in nephrotic children. This is at 
least in part because of loss of immunoglobulins in the 
urine. In addition, protein malnutrition and edema-
tous tissue may contribute to reduced host defenses. 
It is not always possible to prevent the loss of immu-
noglobulins in the urine of patients with persistent, 
heavy proteinuria, but massive edema and malnutri-
126 LANDWEHR: NEPHROTIC SYNDROME MANAGEMENT 
tion are potentially correctable. It is most important 
that the physician be alert to early signs of infection 
in these patients so that they are treated definitively 
and aggressively. 
An increased thromboembolic tendency is an 
additional potential complication of the nephrotic 
syndrome. Although the mechanism is not clearly 
understood, there are data to suggest that a hyper-
coagulable state may exist in association with the 
nephrotic syndrome. Care should be taken that other 
factors, such as venous stasis, which predispose to 
thromboembolism, be avoided in order to minimize 
this risk. It is also important that those providing 
medical care for these patients be especially attuned 
to this problem, so that definitive diagnosis and treat-
ment may be accomplished at the earliest possible 
time. There appears to be no basis for use of anti-
coagulant agents except in documented episodes of 
pulmonary embolus. For unclear reasons, there 
seems to be a predilection for the formation of clots 
within the venous system of the nephrotic kidney. 
Again, it appears that anticoagulants are not in-
dicated except in the occurrence of a pulmonary em-
bolus. 
It has been conclusively demonstrated that pa-
tients with long-standing nephrotic syndrome may 
develop accelerated atherosclerotic disease, leading 
to an increased risk of coronary artery disease and 
acute myocardial infarction; this appears to be re-
lated to prolonged hyperlipidemia. There is an in-
verse relationship between serum albumin and serum 
lipid levels. Any maneuver which improves the serum 
albumin level, such as correction of protein malnutri-
tion, can be expected also to lower serum lipid levels. 
Treatment with clofibrate does not appear to be 
highly effective in treating hyperlipidemia associated 
with the nephrotic syndrome and may be associated 
with severe side effects if the dosage is not reduced to 
correspond to the reduced serum albumin levels. 
The most fundamental concern in management 
of the nephrotic syndrome should be the correction 
of increased glomerular protein leakage. If protein 
loss can be reversed, all secondary problems will re-
solve. Two general considerations relate to abnormal 
protein leakage. First, the physician should be aware 
that the nephrotic syndrome could be a manifestation 
of some reversible systemic process. Any drug, toxin, 
or allergen which could potentially cause the neph-
rotic syndrome should be removed, if possible. Sys-
temic diseases associated with the nephrotic syn-
drome, such as malignancy and chronic infections, 
should be identified and treated definitively. Even 
when malignancy is not curable, reduction in tumor 
mass may lead to resolution of the nephrotic syn-
drome. 
The second approach to treatment of glomerular 
protein leakage involves the use of steroids and im-
munosuppressant agents. It has been shown conclu-
sively in only one disease, nil disease, that these 
agents can predictably reverse glomerular leakage of 
protein; for the rest there is little evidence of efficacy 
of such agents. In nil disease, treatment with predni-
sone, in doses of 40-60 mg/day/m2 body surface area 
in children and 1 mg/day/kg body weight in adults, 
will result in a significant reduction in the level of 
proteinuria within 7 to 28 days. In general, children 
will respond quickly, and their proteinuria will fall 
off rapidly to undetectable levels. Adults tend to re-
spond more slowly and less completely but will usu-
ally have less than 1 gm of protein excretion per day 
within the first 28 days of treatment. After clearing or 
significant reduction in the level of proteinuria, treat-
ment is usually switched to an alternate-day regimen 
and the steroids reduced and subsequently discontin-
ued over the next two to three months. Immuno-
suppressant agents, such as cyclophosphamide, may 
be useful in some patients with nil disease who have 
frequent relapses upon cessation of steroid therapy. 
Recent evidence suggests that these agents may pre-
vent or reduce the frequency of such relapses. 
In addition to the beneficial effect of steroids and 
immunosuppressant agents on the proteinuria of nil 
disease, there is also a recent and ongoing interest as 
to whether these agents may prevent or slow the rate 
of progression of renal failure in glomerulonephritis 
associated with the nephrotic syndrome. The severe 
glomerulonephritis of systemic lupus erythematosus, 
as well as idiopathic membranous and membrano-
proliferative glomerulonephritis, are diseases whose 
prognosis may be improved by these agents; however, 
studies supporting such conclusions have not been 
adequately controlled and remain controversial. 
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On the Prevention of Acute Renal Failure 
(Vasomotor Nephropathy) 
DONALD E. OKEN, M.D. 
Professor of Medicine, and Chairman, Division of N ephrology, Medical College of Virginia, H ea/th Sciences 
Division of Virginia Commonwealth University, Richmond, Virginia 
Acute renal failure following severe trauma, 
shock, transfusion reactions, poisoning, and sepsis is 
characterized by prolonged oliguria, increasing azo-
temia, isosthenuria, and a sodium concentration of 
40-90 mEq/L. Despite the availability of intensive 
medical and surgical care, potent antibiotics, and 
dialysis, this syndrome still carries a mortality rate of 
approximately 50% and once established cannot be 
reversed by any known medical regimen. It is, how-
ever, often preventable, and the purpose of this paper 
is to evaluate the efficacy of the various prophylactic 
measures currently in vogue. 
In searching for means of preventing acute renal 
failure, we should consider three pathophysiologic 
mechanisms involved that, historically, have received 
the greatest attention: 
I. The passive backflow theory, 
2. Tubular obstruction, and 
3. Vasomotor factors. 
According to the passive backflow theory, glo-
merular filtrate is formed at a normal or close to 
normal rate but is absorbed quantitatively and non-
selectively across injured tubular epithelium. The 
tubular obstruction theory presupposes that cell swel-
ling and tubular debris occlude the tubule lumen, 
raise intratubular pressure to the point that filtration 
is seriously reduced, and/or augment the driving 
force for passive backflow of the filtrate formed. The 
vasomotor theory suggests that acute renal failure is 
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the result of a primary failure of glomerular filtration 
because of decreased glomerular capillary filtration 
pressure with or without reduced permeability of the 
filtration surface. 
The renal cortical blood flow of human subjects 
with acute renal failure has been found almost in-
variably to be greatly decreased.1 -• Ifthis decrease in 
blood flow relates only in part to an increased pre-
glomerular vascular resistance as seems evident from 
angiography,5 glomerular filtration must be maxi-
mally suppressed. Although the possibility of inulin 
leakage casts some doubt on the validity of inulin 
clearance measurements which would confirm such a 
near cessation of filtration, micropuncture studies of 
experimental animals with acute renal failure have 
provided unequivocal proof that glomerular filtra-
tion does, indeed, fail. 6 By and large, experimental 
models reveal proximal tubular pressure to be dis-
tinctly low, not elevated as might be suggested by the 
tubular obstruction theory. Although tubular leakage 
of glomerular filtrate has been described by some 
authors, tubular absorption has, for the most part, 
been shown to be markedly decreased, rather than 
increased as suggested by the passive backflow the-
ory.7 Perhaps the most telling argument against this 
theory can be derived from studies of chronically salt-
loaded rats poisoned with mercuric chloride. Such 
animals, allowed l % saline solution in place of tap 
water for a month prior to mercury injection, are 
almost perfectly protected from renal failure. Their 
blood urea nitrogen concentrations and whole kidney 
inulin clearance values are close to normal 24 hours 
after the injection of mercury. Nevertheless, their 
kidneys show tubular necrosis which is just as severe 
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as that displayed by their water drinking counterparts 
with virtually no renal function. 8 If the passive back-
flow theory is not applicable to kidneys with evident 
necrosis of the entire terminal portion of the proxi-
mal tubule, it is highly unlikely to be the major de-
terminant of other types of acute renal failure in 
which tubular damage is far less severe. It is thus well 
to remember that the degree of tubular injury in the 
kidneys of patients with acute renal failure is highly 
variable. Finckh,9 Sevitt, 10 and others have pointed 
out that classical acute renal failure may be found 
without any significant tubular injury, and that no 
correlation exists between the duration or severity of 
renal insufficiency and the degree of tubular injury 
which can be demonstrated. Similarly, acute renal 
failure in man may coexist with scant, if any, evidence 
of tubular obstruction with casts.9 In sum, the over-
whelming bulk of evidence presently affirms that 
acute renal failure relates to a primary cessation of 
glomerular filtration. 
Recently, Flores et al11 have proposed that filtra-
tion failure is caused by endothelial and renal inter-
stitial cell swelling. Such swelling was said to be 
reversible, and renal failure prevented, by ad-
ministering massive doses of mannitol. According 
to the data in that report, however, renal failure was 
not prevented by mannitol administration, merely 
somewhat blunted. In our laboratory, closely follow-
ing the technique used by Flores, we could find no 
significant effect of mannitol therapy. 12 Nor have we 
found a beneficial effect of hypertonic mannitol solu-
tions in myohemoglobinuric acute renal failure other 
than that which could be achieved by volume expan-
sion with saline or plasma alone.13 Mannitol clearly 
increases renal blood flow and helps maintain glo-
merular filtration in dogs subjected to limited hemor-
rhage14; however, as their renal function generally 
returns to normal when renal perfusion pressure is 
restored after hemorrhage whether mannitol is given 
or not, one cannot presume from such studies that 
mannitol prevents acute renal failure. Aortic cross-
clamping has also been reported to cause renal failure 
which is preventable with mannitol,15 but several in-
vestigators studying far larger numbers of animals 
have been unable to duplicate any renal abnormal-
ities at all in similarly treated animals not given man-
nitol.16·17 
A number of clinical reports have suggested that 
mannitol prevents acute renal failure in man, al-
though no prospective study of the efficacy of such 
treatment has appeared. Such a study would, how-
ever, be difficult indeed. Assuming a 1 % overall in-
cidence of renal failure in the total population of 
patients at risk after surgery, burns, trauma, or hem-
orrhage (a deliberate overestimate), at least 2,000 
patients would need to be treated and a comparable 
number employed as controls before a statistically 
meaningful comparison of the two groups could be 
made. Powers et al18 have estimated that the syn-
drome occurs in 0.1 % of patients at risk, a more 
realistic figure that would necessitate the inclusion of 
perhaps 20,000 patients in any controlled study of the 
efficacy of a prophylactic measure. While patients 
subjected to aneurysmectomy develop renal in-
sufficiency more often than others subjected to less 
traumatic surgery, they still have a low risk of renal 
insufficiency unless the aneurysm has ruptured. In 
reviewing 1,659 cases of lower aortic surgery per-
formed in ten centers, Kountz et al1 9 found an overall 
incidence of renal failure of only 3.8%. While the 
physician may be reassured that none of 20 or 50 
patients subjected to major surgery and treated with 
mannitol will develop acute renal failure, there is 
little basis for assuming that mannitol infusions are 
responsible for his good luck. Similar considerations 
apply to the use of furosemide as a prophylactic 
agent. 
The rationale for mannitol's usage rests with the 
suggestion that it maintains renal blood flow, reduces 
renal cell swelling, washes out tubular debris, serves 
to expand vascular volume, and induces urine output 
if filtration still persists. This is an impressive list of 
potential benefits, but the bulk of controlled experi-
ments show cell swelling and tubular obstruction not 
to be critical to the development of acute renal fail-
ure. The syndrome can be induced readily in rats with 
congenital diabetes insipidus, excreting (and drink-
ing) a volume equal to 80% of their body weight each 
day. 20 Thus, the maintenance of urine volume and 
washout of tubular casts is not critical to the pre-
vention of acute renal failure, whether this is achieved 
with furosemide or with mannitol. A response to 
either agent proves that acute renal failure does not 
yet exist, as urine can only be formed when filtration 
is ongoing. 
Whether renal failure develops or not depends 
largely on the type, as well as on the severity, of the 
underlying injury sustained. Shock, for example, is a 
major factor. While brief and modest hypotension 
may, at times, lead to renal failure, the syndrome is 
far more likely to occur if shock is of long duration or 
poorly controlled. Volume depletion also plays a sig-
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nificant pathogenetic role, adequate volume replace-
ment being the most important single therapeutic 
modality available for the prevention of renal shut-
down. The adequacy of fluid therapy cannot be 
merely assumed, however, but requires documenta-
tion of adequate weight gain, appropriate changes in 
urinary sodium concentrations and osmolality, and 
where needed, measurement of central venous pres-
sure and blood volume. Sepsis may predispose to 
renal insufficiency not only on the basis of toxemia, 
but also by the activation of intravascular coagu-
lation.21 With prompt and vigorous treatment offiuid 
volume deficits, the restoration of cardiac output to 
reasonable levels , and vigorous treatment of sepsis, 
the incidence of acute renal failure has become far 
lower than in previous times, a reduction which is as 
apparent in centers where mannitol and furosemide 
are not used as "preventive agents" as in those where 
they are. 
While acute renal failure owing to trauma and 
shock is far less prevalent nowadays, a new threat has 
emerged with the widespread use of the amino-
glycoside antibiotics . These agents are excreted essen-
tially unchanged primarily by the kidney. Any im-
pairment of glomerular filtration rate (GFR), 
whether because of organic disease or as a functional 
result of heart failure or dehydration, causes accumu-
lation of these agents to a level which may be nephro-
toxic. Unlike the idiosyncratic reactions to other anti-
biotics that occur in a very small percentage of the 
population, renal toxicity can be expected in any 
patient exposed to abnormally high concentrations of 
aminoglycosides. The setting in which these agents 
are used is one that so frequently results in some 
compromise in renal function that toxic levels are 
easily attained. Unlike other forms of acute renal 
failure, that following aminoglycoside overdosage 
may be irreversible. 
How can we prevent this common and very seri-
ous complication? First, the aminoglycosides should 
be used only when less toxic antibiotics cannot be 
substituted. Second, renal function should be fol-
lowed closely if these agents are to be given. Various 
formulae are used as guides to appropriate gen-
tamicin dosage in the face of reduced renal function, 
and not one seems clearly superior to the others. All, 
however, rely on the reasonably accurate assessment 
of renal function. Normal serum creatinine concen-
trations in non-gravid adults range from 0.6 to 1.6 
mg%. Thus, a value of 1.2 mg% in one patient may be 
normal; in another, it may be twice normal and in-
dicative that the G FR is reduced by one half. If one 
abruptly loses all renal function, the serum creatinine 
obtained two days later will be perhaps 3 mg% and 
will rise progressively thereafter. It certainly would be 
erroneous to assume that a creatinine concentration 
of 3 mg% in such a patient means that the GFR is one 
third of normal and administer gentamicin (or the 
other aminoglycosides) accordingly, when, in fact, 
the G FR is almost nil. The way out of the dilemma is 
to routinely measure the serum creatinine concentra-
tion of any patient receiving these drugs on the day 
after treatment is started. Any significant increase 
should prompt a repeat determination 12 or 24 hours 
later, as should any circumstance likely to lead to 
worsening renal function. As serum creatinine con-
centrations truly reflect renal function only when they 
are stable, it is imperative that serum antibiotic levels 
be monitored to serve as the guide to dosage if the 
creatinine concentrations are rising. 
Nephrotoxic renal damage may be superim-
posed on preexisting renal impairment and, as pre-
viously stated, may be irreversible. Only by treating 
the aminoglycosides with the greatest respect and 
closely monitoring the renal function of patients re-
ceiving these drugs can overdosage and the resultant 
renal failure be avoided. 
To summarize, the best evidence available at 
present indicates that acute renal failure represents a 
sustained and severe decrease in G FR. Tubular fac-
tors are thus of secondary importance, and the term 
"acute tubular necrosis" (ATN) is not pathologically 
appropriate. Vasomotor nephropathy seems a better 
term, and one we have adopted for this syndrome22 
which in many circumstances is largely preventable 
by the prompt and vigorous restoration of fluid defi-
cits and cardiac output, as well as the treatment of 
sepsis. Unfortunately, such therapy may be only mar-
ginally successful in some instances (for example, 
overwhelming sepsis, acute hemorrhagic pan-
creatitis ), but there is scant evidence that either man-
nitol or furosemide protects patients from renal fail-
ure. Rather than relying on such agents, efforts 
should be made to maintain normal fluid volume and 
cardiac output in all cases at risk of vasomotor ne-
phropathy. 
Renal failure owing to gentamicin and other 
aminoglycoside antibiotics is a result of improper 
attention to dosage relative to a patient's renal func-
tion. Close attention to renal function can largely 
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eliminate this common cause of renal failure. swelling in ischemic renal damage and the protective effect of 
hypertonic solute. J Clin Invest 51: 118-126, 1972. 
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Pyelonephritis 
WILLIAM F. FALLS, JR., M.D. 
Medical Service, Veterans Administration Hospital, and Department of Medicine, Medical College of Virginia, 
Health Sciences Division of Virginia Commonwealth University, Richmond, Virginia 
The purpose of this paper is to review current 
thinking about pyelonephritis. Pyelonephritis may be 
defined as a "bacterial infection of the kidney which 
affects the parenchyma, the pelvis, and the calyces. It 
occurs in two forms, acute and chronic."' 
Clinically, acute pyelonephritis is characterized 
by the symptoms of dysuria, frequency, urgency, 
chills, fever, and flank pain. The urine sediment con-
tains numerous white blood cells, bacteria, and white 
blood cell casts (Fig I). A quantitative culture of the 
first voided urine in the morning yields a growth of 
greater than JOI' colonies per ml. Renal histologic 
examination reveals an acute interstitial inflamma-
tory reaction with polymorphonuclear leukocytes 
and microabscess formation (Fig 2). If the infection 
remits either spontaneously or with antibiotic ther-
apy, the involved areas may heal with formation of a 
contracted, fibrotic scar. In contrast to the acute in-
fection, chronic pyelonephritis may be totally asymp-
tomatic. Examination of the urine sediment usually 
shows changes similar to those in acute disease except 
that the quantities of cells and casts may be less 
remarkable. The classic pathologic picture of chronic 
pyelonephritis includes interstitial infiltration by 
mononuclear cells, scarring, tubular dilatation (thy-
roidization) and periglomerular fibrosis (Fig 3). The 
typical chronic pyelonephritic kidney is shrunken, 
contains multiple scars, and is atrophic. 
The pathologic picture of pyelonephritis is not 
entirely specific, particularly in the chronic state 
where other processes which cause an interstitial 
inflammatory reaction may give a similar appear-
ance. An incomplete list of nonbacterial causes of 
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chronic interstitial nephritis includes: analgesic 
abuse, other drug toxicity, tuberculosis, sarcoidosis, 
gouty nephropathy, hypercalcemic nephropathy, and 
ischemic vascular disease. 2 Initially, these disorders 
may be suspected because of the presence of sterile 
pyuria, but later, superimposed bacterial infection 
may cloud the picture. 
Bacteria invade the kidney by two principal 
routes: hematogenous and retrograde.3 Hemato-
genous spread occurs infrequently, but when it does, 
it is the means whereby most staphylococcal and 
streptococcal infections are initiated in the kidney. 
These infections may be severe and associated with 
multiple abscess formation . Most bacterial infections 
of the kidney are caused by gram-negative organisms 
that reach the kidney via retrograde spread from the 
lower urinary tract; the natural habitat of the major-
ity of these organisms is the gastrointestinal tract 
from which they spread to the urethra and then into 
the bladder and up the ureters. Approximately one 
fourth of all bacterial infections involve the urinary 
tract, but only a portion of these ascend above the 
bladder to the renal parenchyma. 
Several factors are now recognized as being of 
major importance in the pathogenesis of urinary tract 
infection, the first of which is sex. There is clearly a 
higher incidence in females at all ages but particularly 
in the childbearing years. Only in later life with the 
a:dvent of prostatic hypertrophy and associated ob-
structive uropathy does the incidence tend to increase 
in the male. The increased incidence in females prob-
ably relates to the shorter urethra, the absence of the 
antibacterial action of prostatic fluids, and trauma 
during intercourse. Recently it has also been recog-
nized that disturbances in the bacterial resistance of 
the vaginal vestibule secretions may be the factor 
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Fig I-Urine sediment from a patient with acute pyelonephritis, showing white blood cells, a white blood cell cast, a granular cast and 
numerous bacteria ( X 1,000). 
which initially allows bacterial colonization of the 
urethra in females.• 
Instrumentation of the urinary tract is frequently 
associated with introduction of bacteria into the 
bladder. Unfortunately, the instrumentation is usu-
ally undertaken for evaluation of an anatomically 
abnormal tract. Bladder urine is normally sterile. 
When pathogenic organisms are introduced into the 
bladder of a normal, unobstructed animal or man, 
they are rapidly cleared because of the combined 
effects of the bacteriostatic properties of normal 
urine, the dilution of organisms by voiding, and the 
resistance of the bladder mucosa to bacterial coloni-
zation.5 On the other hand, in the obstructed state 
there is a residual pool of relatively stagnant urine; 
the bacterial clearing mechanisms are no longer oper-
ative and infection ensues. In this context neurogenic 
bladder dysfunction may have the same propensity to 
infection as overt obstructive uropathy. 
In recent years numerous studies have indicated 
that ureteral reflux is probably the most important 
factor which allows for initiation and perpetuation of 
renal parenchymal infection. Congenital reflux be-
comes a problem in early childhood and is usually 
caused by an abnormal placement of the ureter in the 
bladder wall. 6 In the immature kidney it is likely that 
even sterile reflux may result in calyceal scarring and 
contracture of the parenchyma. This type of reflux 
carries an ominous prognosis and frequently requires 
surgical correction . Acquired reflux (Fig 4) may ap-
pear in older individuals and may be related to blad-
der infection, adjacent bladder diverticulae, or neuro-
genic mechanisms.7 When reflux is severe, it may be 
associated with intrarenal reflux in the polar regions 
of the kidney. Some authorities think that this may be 
the cause of atrophic pyelonephritis.8 
Dilatation of the ureters, because of pressure 
from the expanding uterus, and the smooth muscle 
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Fig 2-Light microscopic representation (H & Estain) of a renal biopsy section, showing the picture of acute pyelonephritis. Glomerular 
architecture is relatively well maintained, but there is a marked interstitial inflammatory reaction with both polymorphonuclear and 
mononuclear leukocytes. A white blood cell cast fills the collecting duct on the right. (X 80). 
relaxing effects of high estrogen concentrations, may 
predispose to the development of pyelonephritis in 
pregnancy.a Fully 30% of pregnant patients with 
asymptomatic bacilluria will have an episode of acute 
pyelonephritis during a given pregnancy if left un-
treated .9 
Controversy continues to surround the issue of 
whether or not diabetes mellitus predisposes to the 
development of pyelonephritis, and recent evidence 
suggests that its incidence is higher in diabetic 
women. 1° Clearly, when pyelonephritis develops in a 
diabetic patient, the infection itself is more likely to 
be severe. 
The cortex appears to be relatively resistant to 
bacterial colonization, and most parenchymal infec-
tions begin in the medulla where increased suscepti-
bility to infection probably relates to the lower blood 
supply to the medulla, the hypertonicity of the med-
ullary interstitium which depresses phagocytosis, the 
high level of ammonia which interferes with activa-
tion of the complement system, and the tendency for 
granulocytes to emigrate from the medullary area.a 
Eighty-five percent of new urinary tract infec-
tions which develop outside the hospital are caused 
by Escherichia coli organisms and the remaining 15% 
by other organisms, most of which are also gram-
negative.11 When infection develops in the hospital 
setting or occurs after instrumentation, the bacterial 
flora is likely to be different and is usually composed 
of gram-negative organisms with a greater degree of 
bacterial resistance than E coli. 
The main danger of bacterial infection of the 
kidney relates to its complications. There are a num-
ber of these and one which has generated much recent 
interest about its pathogenesis is atrophic pyelone-
phritis.8 It is now clear that this condition develops in 
early life, is associated with high grades of reflux, and 
may terminate in end-stage renal disease at an early 
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Fig 3-Light microscopic autopsy section (H & E stain) from a patient with chronic pyelonephritis. Marked interstitial inflammatory 
reaction in association with scarring, tubular dilatation, and periglomerular fibrosis is present. Secondary arteriolar thickening has also 
occurred ( X 20). 
age if the reflux is not corrected. It has been suggested 
that the small shrunken kidney seen in later life may 
be the result of atrophic pyelonephritis in childhood. 
Papillary necrosis may be one of the most devas-
tating complications of urinary tract infection, partic-
ularly if it occurs in diabetes mellitus with obstruc-
tion . This constellation of disturbances was formerly 
associated with a high frequency of sepsis and death, 
but it is seen less frequently since the advent of mod-
ern antibiotic therapy. At the present time it is more 
likely that papillary necrosis may present insidiously 
with slow deterioration in renal function, perhaps in 
conjunction with the passage of small pieces of papil-
lary tissue in the urine. Contemporary studies12 sug-
gest that this latter picture may be seen more fre-
quently with another underlying disease such as 
analgesic abuse or sickle cell disease, rather than as a 
manifestation of pyelonephritis (Fig 5) . 
Struvite stone formation is another common 
complication of urinary tract infection and is caused 
by infection with urea-splitting organisms, particu-
larly those of the proteus species. This type of infec-
tion is seen all too frequently in patients with obstruc-
tive uropathy or neurogenic bladder dysfunction. 
Under either of these circumstances a continuous 
cycle of stone formation-infection-stone formation 
may develop. The composition of most "staghorn" 
calculi which develop in an obstructed, infected uri-
nary tract is struvite. Infection is virtually impossible 
to clear from the urine in this situation . 
Perinephric abscess is an infrequent but impor-
tant complication of urinary tract infection because 
its onset may be insidious and it may be associated 
with remarkably minimal changes in the urine sedi-
ment. It may present as a fever of unknown etiology, 
and the use of modern radiographic techniques, such 
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Fig 4-Voiding cystourethrogram in a patient with acute cystitis 
and bilateral reflux. Moderate ureteral dilatation is present and the 
contrast medium refluxes into the calyceal system. The left calyceal 
system is also clearly dilated . 
as gallium scanning and CT scanning, may be of 
great diagnostic aid. In addition, sonography of the 
retroperitoneum and abdomen may be of diagnostic 
help. 
Gram-negative sepsis remains a frequent compli-
cation of urinary tract infection and may be associ-
ated with instrumentation or the presence of an in-
d wel I ing urethral catheter; therapy requires 
aggressive treatment with measures to support the 
circulation while administering a bactericidal antibi-
otic. 
Whether or not chronic pyelonephritis pre-
disposes to the development of severe hypertension 
continues to be a subject of debate. Some evidence in 
both children and adults would suggest that the 
chronically scarred kidney may be associated with 
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Fig 5-Retrograde urogram in a patient with papillary necrosis 
secondary to analgesic abuse. There is marked distortion of the 
calyceal system on the right. Necrotic, papillary debris is present in 
several calyces, displacing the contrast medium and giving rise to 
the characteristic "ring" sign. 
activation of a pressor hypertensive mechanism; 13 
however, most patients with chronic infection remain 
normotensive or, at worse, mildly hypertensive. Per-
haps a more important aspect of the association is the 
fact that progression of pyelonephritis, like that of 
any other type of renal disease may be accelerated by 
the presence of superimposed hypertension; there-
fore, elevated blood pressure in a patient with pyelo-
nephritis should be treated vigorously. 
A number of disturbances in relation to preg-
nancy have been correlated statistically with the pres-
ence of urinary tract infection. The most notable of 
these are anemia and decreased birth weight of the 
fetus. After a period of skepticism about the relation-
ship of these abnormalities to infection, recent studies 
have confirmed their association.9 As mentioned ear-
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Fig 6- Comparison of mean ± SEM values for C,,,, CPAH, and FF between initial measurements early after injury and similar deter-
minations after more than five years in 18 patients with spinal cord injuries and persislent bacilluria. 
lier, there is a high incidence of acute pyelonephritis 
in pregnant females with bacill uria, and this condi-
tion, clearly, should be treated.9 
For years pyelonephritis was considered to be a 
major cause of end-stage renal disease. Careful evalu-
ation of patients entering dialysis and transplant pro-
grams, however, has indicated that this is not the 
case.14 It is likely that many of the cases of interstitial 
nephritis which were thought to be caused by infec-
tion were in actuality the end result of one of the 
other causes of interstitia l disease mentioned earlier. 
Present estimates would suggest that no more than 
15% of the patients reaching end-stage disease have 
infection as the primary cause of renal failure and 
virtually all of these are complicated by the presence 
of stones, reflux, or other anatomic disturbance. 
Information a bout the natural history of urinary 
tract infection in man is still incomplete. As noted 
above, end-stage renal disease in the absence of an 
anatomic or neurologic defect in the urinary tract is 
rare despite the frequency of culture-proven baci l-
luria . We have recently attempted to define more 
clearly the association of chronic bacill uria and dete-
rioration in renal function by a' prospective analysis 
of the changes in inulin clearance (C1n) and PAH 
clearance (CPAH) in a group of patients with per-
sistent bacilluria (spinal cord injury patients). C 1n is 
an accurate measure of the glomerular filtration rate 
and CPAH indicates the renal plasma flow. 
Figure 6 demonstrates that at a mean period of 
five years after the initial determinations, a statisti-
cally significant reduction in mean CPAH from an 
initial value of643 ml/ min shortly after injury to 556 
ml / min at the time o f study had occurred in 18 study 
patients. Over the same period, there was no signifi-
cant change in C1n; there was also a significant reduc-
tion in the filtration fraction (FF). This index reflects 
the ratio of C1n/ CPAH a nd is an indicator of the state 
of perfusion in the kidney. Diseases which produce 
renal ischemia may be associated with a low FF. 
Each of the study patients had a neurogenic bladder 
and persistent bacilluria. A number had experienced 
one or more severe complications such as renal 
stones, ref! ux, or sepsis. Yet, at the time of study, all 
had adeq uate urinary drainage. These data suggest 
that the re may be insidious d amage occurring to the 
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kidneys of these patients; however, barring superim-
position of some other insult, renal failure is unlikely 
to be the cause of their death . 
There will always be differences of opinion about 
the work-up and therapy of patients with urinary 
tract infection. Outlined below are some principles 
which are generally applicable to these issues: 
1. A quantitative culture, colony count, and an-
tibiotic sensitivity determination should be 
performed in all pregnant women and in all 
individuals suspected of having a urinary 
tract infection. 
2. A patient with the typical clinical picture of 
acute pyelonephritis or gram-negative sepsis 
should be treated with a bactericidal antibi-
otic to which the organism is sensitive for at 
least 10 days. 
3. Radiographic studies including an intra-
venous pyelogram and voiding cystourethro-
gram should be done after the first episode of 
acute pyelonephritis in the adult male and in 
all children. Similar studies should be done in 
any female with recurrent infection or an ele-
vated serum creatinine. Further urologic eval-
uation should be done in all patients in whom 
these studies identify a structural abnormal-
ity. Surgical correction of obstruction and se-
vere reflux should be undertaken. Mild reflux 
in children may be observed during a period 
of antibiotic therapy and can be expected to 
disappear in 50% of cases by age 6 years and 
in 65% by age 14 years.6 
4. The clinical picture of cystitis and asympto-
matic bacilluria may be treated with bacte-
riostatic agents . If recurrence occurs, ,the 
above-mentioned radiologic studies should be 
done. If these are negative, prophylactic or 
suppressive therapy may be tried. In the fu-
ture, tests for antibody coating of bacteria 
may be helpful in differentiating upper tract 
infection with renal parenchymal in-
volvement from lower tract infection. 15 
5. Reculture should be done after the com-
pletion of therapy for a urinary tract infection 
and on several occasions over the next two 
years to determine the presence of recurrence 
or reinfection . 
In summary, current thoughts about the patho-
genesis, natural history, complications, and manage-
ment of pyelonephritis have been reviewed. It is now 
clear that chronic urinary tract infection in the ab-
sence of some anatomical disturbance or complica-
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tion seldom leads to renal failure. Efforts should 
therefore be directed toward discovering and correct-
ing derangements in the anatomical integrity of the 
urinary tract at an early stage of infection. 
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Evaluation of an Abnormal Urinalysis in the 
Asymptomatic Patient 
DOUGLAS M. LANDWEHR, M.D., Ptt.D. 
Associate Professor of Medicine, Division of N ephrology, and Director, Hemodialysis Unit, Medical College of 
Virginia, Health Sciences Division of Virginia Commonwealth University , Richmond, Virginia 
Physicians are occasionally presented with the 
problem of evaluating a patient who has an abnormal 
urinalysis 1 but who has no other sign or symptom of 
genitourinary (GU) tract disease. For example, pa-
tients may present with hematuria, pyuria or slight 
proteinuria, but they may have no other clinical or 
laboratory abnormality to suggest glomerulonephri-
tis, renal failure, urinary tract infection, obstruction, 
hypertension, or stones. There are a wide variety of 
lesions which may produce such isolated abnormal-
ities,2·3 and a rational approach is indispensable in 
preparing an efficient and definitive diagnostic plan. 
The urinalysis may be abnormal because of the 
presence of red blood cells, white blood cells, or 
excessive amounts of albumin. To understand the 
diagnostic possibilities of such abnormalities it is use-
ful to begin by considering the sensitivity of the rou-
tine urinalysis (Table l ). Detection of the presence of 
only l + albuminuria requires albumin in a concen-
tration of 30 mg/ 100 ml. In the case of red cells and 
white cells in a centrifuged urine specimen, our limits 
of detection extend to recognition of a single cell 
under the microscope. Let us next consider the quan-
tity of each of these elements in a single milliliter of 
blood. Blood normally contains 4 gm of albumin per 
100 milliliters, which is equivalent to 40 mg/ ml. 
White blood cells number approximately 10,000/ 
mm3 of blood, which is equivalent to 10 million / ml. 
Similarly, 5,000,000 red blood cells per mm3 of blood 
is equivalent to 5 billion / ml. Let us assume that some 
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abnormality in the GU tract leads to the loss of l ml 
of blood (a relatively small amount) into the urine 
each day. Assuming a modest urine volume of 1,000 
ml / day, let us then examine what would be the con-
centration of the individual components of the urine 
relative to the limits of detection. In the case of 
albumin, 40 mg from l ml of blood distributed in one 
liter of urine would result in a concentration of only 4 
mg/ 100 ml. This is well below our detection limit of 
30 mg/ 100 ml for a l + measurement. White cells 
from I ml of blood distributed in 1,000 ml of urine 
would result in a concentration of 100,000/ 10 ml. If 
one takes 10 ml of that urine, as with the standard 
urinalysis, centrifuges it and resuspends the sediment, 
all 100,000 white cells are potentially identifiable; 
with red blood cells, there would be an even higher 
number of identifiable units in the urinalysis. 
There are certain important conclusions con-
cerning the routine urinalysis which can be drawn 
from the above consideration: on one hand, it is 
evident that we can detect small amounts of bleeding 
into the urine by the presence of red blood cells; on 
the other hand, relatively large amounts of blood, 20-
40 ml/day, depending on urine volume, must be pres-
ent to give detectable albuminuria. Such quantities 
would contain large numbers of red blood cells and 
thus result in gross hematuria. Albuminuria, detected 
on the routine urinalysis and accompanied by only 
microscopic hematuria, could, therefore, not reflect 
simple bleeding in the GU tract. Albumin can be 
separated from blood cells only in the glomerulus 
and, thus, glomerular abnormalities must exist if 
there is detectable albuminuria in the routine urinaly-
sis in the absence of gross hematuria. 
MCV QUARTERLY 14(3):140-143, 1978 
LANDWEHR: ABNORMAL URINALYSIS IN THE ASYMPTOMATIC PATIENT 141 
TABLE 1 
Sensitivity in Detection of Abnormalities of the Urinalysis 
Albumin 
Limits of detection 30 mg/ 100 ml 
Content in I ml blood 40 mg/ L 
(4.0 gm/ 100 ml) 
Concentration when I ml blood 40 mg/ L 
mixed with I liter urine (4.0 gm/ 100 ml) 
In view of the above considerations, let us now 
consider the evaluation of the patient with an abnor-
mal urinalysis. Asymptomatic albuminuria, with or 
without microscopic hematuria, indicates glomerular 
leakage of protein. As we are considering asympto-
matic albuminuria, this would involve only mild de-
grees of protein loss. Proteinuria greater than 3.5 gm/ 
day would not be asymptomatic or isolated, since it 
would be accompanied by manifestations of the 
nephrotic syndrome. Causes of asymptomatic al-
buminuria may be divided into functional and patho-
logical disturbances. It is referred to as functional 
when it is not permanent and when it occurs in asso-
ciation with other temporary physiological distur-
bances. Examples of this include albuminuria which 
occurs with fever, exacerbations of congestive heart 
failure, or severe exertion. Another kind of functional 
proteinuria is that which is detectable in certain per-
sons after prolonged standing. Such postural or or-
thostatic proteinuria usually involves excretion of less 
than 1.5 gm of protein per day . Long-term follow-up 
of most patients with postural proteinuria have in-
dicated a good prognosis; however, in somewhat less 
than 10% of cases, postural proteinuria is associated 
with unequivocal glomerular disease, and here the 
prognosis is more guarded. 
Asymptomatic albuminuria also occurs as a 
predecessor of serious disease in some patients and is 
termed pathologic proteinuria. In general, certain 
forms of glomerulonephritis, such as idiopathic mem-
branous and focal sclerosing glomerulonephritis, 
may initially present with isolated asymptomatic pro-
teinuria . After a period in which there are no other 
signs or symptoms of renal disease, proteinuria either 
increases to nephrotic levels or progressive renal fail-
ure begins. 
Having spoken of this entity as isolated and 
asymptomatic proteinuria, we are presupposing that 
the patient has already had a careful clinical and 
Pyuria 
I WBC/ HPF 
10,000,000 
(10.000/ mm') 
I 0,000,000/ L 
100,000/ 10 ml 
Hematuria 
I RBC/ HPF 
5,000,000,000 
(5 ,000,000/ mm') 
5,000,000,000/ L 
50,000,000/ 10 ml 
laboratory evaluation which has not disclosed other 
significant nephrologic abnormalities. No further 
evaluation or treatment is indicated. Renal biopsy 
does not contribute importantly other than providing 
a more definitive prognosis. At the present time even 
those types of pathologic proteinuria which may ini-
tially present as asymptomatic proteinuria do not 
appear to be amenable to therapy. 
Pyuria may be defined as the presence of more 
than four white blood cells per high-power field from 
a carefully collected urine specimen. It is usually at-
tributable to infection in the GU tract; however, on 
rare occasion, it may occur in the absence of classical 
infection and without other abnormalities in the uri-
nalysis. In these circumstances pyuria deserves spe-
cial consideration. Tuberculous infection of the GU 
tract, as well as infection with fungi, should be con-
sidered. Nephritis associated with systemic lupus er-
ythematosus is a recognized cause of a urinalysis 
which contains abnormal numbers of white blood 
cells in the absence of other signs and symptoms of 
renal disease. Rejection of the transplanted kidney 
and other forms of interstitial nephritis may also on 
occasion present initially with asymptomatic isolated 
pyuria. 
Evaluation of asymptomatic pyuria should be 
undertaken when it is demonstrated in repeated uri-
nalyses from carefully collected urine samples. Cul-
tures for tuberculosis are indicated and intravenous 
pyelography may be useful in demonstrating the 
characteristic lesions of GU tract tuberculosis. In the 
immunosuppressed patient or in the patient with rec-
ognized systemic fungal diseases, special cultures for 
fungi should also be done. A careful clinical and 
laboratory search for evidence of syste111ic lupus er-
ythematosus should be carried out and agents such as 
antibiotics and diuretics, which may potentially pro-
duce an interstitial nephritis, discontinued. Treat-
ment, of course, is dictated by the specific diagnosis. 
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TABLE 2 
The Most Frequent Causes of Asymptomatic Hematuria 
Urinary tract infection 
Stones 
Prostatic disease 
Tumors: 
25% incidence with gross hematuria 
2% incidence with microscopic hematuria 
Glomerulonephritis 
Interstitial nephritis 
Cystic kidney disease 
Papillary necrosis 
Tuberc ulosis 
Hemorrhagic states 
Vascular malformations 
Hematuria is the most troublesome and poten-
tially serious problem when it is encountered as an 
isolated finding in the asymptomatic patient. Abnor-
mal numbers of red blood cells may enter the urine 
anywhere in the kidney or urinary tract, and may be 
caused by such diverse lesions as glomerulonephritis, 
benign and malignant masses, cysts, infection, and 
hemorrhagic states.4 •5 The most frequent causes of 
asymptomatic hematuria are presented in Table 2. 
The incidence of each of these entities varies consid-
erably with the age, sex, and racial background of the 
patient. Although there is a significant incidence of 
neoplastic lesions with microscopic hematuria, a tu-
mor etiology is even more likely in the presence of 
gross hematuria. 
Evaluation of asymptomatic hematuria should 
begin with a review of some aspects of the patient's 
history. The patient should be questioned about the 
timing of the hematuria. When it occurs upon initia-
tion of voiding, an anterior urethral bleeding site is 
suggested. When hematuria is only evident at the 
termination of voiding, a site near the posterior ure-
thra, bladder neck, or trigone is more likely. Hema-
turia equally present throughout urination usually 
has a source above the level of the bladder. Recurrent 
episodes of either gross or microscopic hematuria, in 
association with upper respiratory tract illnesses, im-
munization, or exercise, suggest glomerulonephritis. 
Symptoms of stone disease and infection should be 
sought. Polycystic kidney disease and sickle cell dis-
ease frequently produce hematuria and may be sug-
gested from a careful review of the patient's family 
history. Unusual bleeding other than in the GU tract, 
as well as the use of anticoagulant medications, may 
lead one to suspect an underlying coagulopathy. 
Careful performance of the urinalysis by the re-
sponsible physician is also important. As noted 
above, when microscopic hematuria is accompanied 
by qualitatively detectable albuminuria, a glomerular 
origin is likely . Red blood cell casts can only form 
within the tubules of the kidney and indicate a renal 
origin for hematuria . Early morning urine, as well as 
urine obtained after exercise, should be examined 
since red cell casts may be more prevalent under these 
circumstances. 
As outlined in Table 3, special studies may be 
required in the evaluation of hematuria. An intra-
venous pyelogram should be obtained in most cases; 
it is especially useful for demonstrating mass lesions 
in the GU tract, as well as stones and papillary necro-
sis. Cysts may be further evaluated with sonography 
if there is any question as to malignancy; absence of 
internal echoes means that a cyst is probably benign. 
Cyst puncture under sonographic control allows aspi-
ration of fluid for cytological study, as well as in-
stillation of contrast media. Demonstration of an 
irregular cyst wall strongly suggests a renal cell carci-
noma. 
When no cause for hematuria is apparent from 
the intravenous pyelogram, or when a lesion requires 
further definition , cystoscopy should be carried out. 
This may permit direct visualization of bleeding sites 
and, with great care, may allow sampling of urine 
from individual ureters. Additionally, retrograde 
pyelography may disclose lesions not demonstrable 
by an intravenous pyelogram. 
In cases in which cystoscopy, as well as intra-
verious pyelography, fails to disclose a source for 
hematuria, renal arteriography should be considered. 
In this way masses too small to demonstrate by the 
TABLE 3 
Special Studies for Asymptomatic Hematuria 
I. INTRA VENOUS PYE LOG RAM - tumors, cystic disease, 
stones, papillary necrosis. 
2. SONOGRAM------- simple cyst VS tumor. 
3. CYSTOSCOPY lower GU tract lesions, 
(RETROGRADE PYELOGRAPHY) evaluation of ureteral 
urine. 
4. R ENA L ARTERIOGRAPHY -- cyst vs tumor, occult 
tumors, vascular mal-
forma tions. 
5. RENAL BIOPSY---- glomerulonephritis, 
interstitial nephritis. 
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previous techniques may be localized. Additionally, 
vascular malformations leading to hematuria may be 
demonstrable only with arteriography. When arteri-
ography does not disclose an abnormality and when 
no bleeding is found from the lower urinary tract by 
cystoscopy, hematuria is probably caused by inter-
stitial renal disease or glomerulonephritis. Interstitial 
nephritis may result from commonly used drugs such 
as diuretics and antibiotics. Such agents should be 
discontinued and the patient followed closely to de-
termine whether the hematuria resolves. Glomerular 
lesions are probably the most frequent cause of iso-
lated hematuria of renal origin in the asymptomatic 
patient who has no lesion demonstrable by pye-
lography or arteriography. In general, glomerular le-
sions which produce only hematuria and are not as-
sociated with other systemic abnormalities have an 
excellent prognosis. They may occur at any age but 
are more frequent in children and young adults. 
However, other more severe forms of glomerulone-
phritis may occasionally present with asymptomatic 
isolated hematuria. Such disease processes include 
hereditary glomerulopathies, collagen vascular dis-
ease, and unresolved poststreptococcal glomerulone-
phritis. Thus, a diligent search for nonrenal signs and 
symptoms of these diseases, as well as appropriate 
laboratory tests, should be carried out. 
In the patient with hematuria of renal origin and 
normal renal arteriography, it may be important to 
establish a definitive diagnosis by renal biopsy. If this 
is not done, hematuria may recur or persist, and 
physicians caring for these patients in the future may 
be concerned over neoplastic lesions which might 
have been missed in previous investigations. Fre-
quently these concerns lead to multiple, unnecessary 
arteriographic and cystoscopic procedures. Per-
cutaneous renal biopsy in most such patients will 
provide a definitive diagnosis and thus obviate fur-
ther invasive diagnostic procedures. Additionally, the 
biopsy may be useful in providing prognostic data on 
the potential severity of the glomerular lesion . 
As can be seen from the above discussion, evalua-
tion of an abnormal urinalysis from an otherwise 
healthy individual involves consideration of a large 
number of potential diagnoses. If the meaning of 
individual abnormalities in the urinalysis is not care-
fully considered, valuable time may be wasted and 
inappropriate and expensive procedures may be per-
formed. The general principles discussed above, 
however, allow for a rational and effective approach 
to this problem. 
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The End-Stage Renal Disease Program 
WILLIAM K. STACY, M.D. 
Associate Professor of Medicine, Chief; Hemodialysis Center, McGuire Veterans Administration Hospital, 
Richmond, Virginia 
By the mid 1960s it had been clearly demon-
strated that the lives of people with total, permanent 
kidney failure could be indefinitely prolonged with 
the artificial kidney and that an acceptable propor-
tion of kidney transplants would be successful. The 
extraordinary cost of this form of therapy, however, 
prohibited its application to the majority of patients. 
A strong lobby of health care providers and con-
sumers sought government assistance and in the 
spring of 1972 Congress passed Public Law 92-603 
(Section 2991) which provided for payment of 80% of 
costs for management of end-stage renal disease 
(ESRD) for all persons eligible for Social Security 
benefits, regardless of their ability to pay. This law 
established what is, in effect, a national health insur-
ance program for people with end-stage renal disease 
and it may well be a model for future national health 
insurance programs. 
Until early 1977, the ESRD program was admin-
istered through the Bureau of Health Insurance of the 
Social Security Administration and the Bureau of 
Quality Assurance of the Public Health Service; after 
that the responsibility for all administrative activity 
was consolidated in the newly formed Health Care 
Financing Administration (HICFA). 1 Primary re-
sponsibility for medical matters was assigned to the 
Health Standards and Quality Bureau and fiscal mat-
ters to the Medicare Bureau. 
To facilitate administration at the local level, the 
nation was divided into 32 ESRD networks by the 
Secretary of Health, Education and Welfare accord-
ing to established referral patterns, modalities of 
services offered, and population (Fig I ). 2 The net-
work boundaries do not necessarily follow state or 
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other government lines. Virginia is divided among 
three networks. The large central portion of the state 
and the whole of West Virginia make up Network 30. 
The Virginia counties of Scott and Washington are in 
Network 18 with Tennessee, Alabama, and Missis-
sippi . Four northern Virginia counties, Arlington, 
Fairfax, Loudoun, and Prince William, have been 
included in Network 23 with the District of Columbia 
and five Maryland counties. This division of Virginia 
was considered consistent with established referral 
patterns and medical communications; funding for 
the establishment of these networks was made avail-
able in August 1977, and all of them are now active. 
Network 30 was organized in 1977 as a free-standing, 
non-profit corporation called the ESRD Network 
Coordinating Council of the Virginias, with offices in 
Richmond. 
The governing body of the network is the Net-
work Coordinating Council (NCC). Federal regula-
tions require that each approved ESRD care facility 
provide a representative to this body and that all 
health care disciplines concerned with ESRD be rep-
resented including physicians, nurses, social workers, 
dietitians, technicians, and administrators . Con-
sumers must also be represented but not as a major-
ity. 
The objective of the network is to assure that all 
persons with ESRD have access to appropriate care. 
The coordinating council is concerned with mon-
itoring the quality of care and encouraging the appro-
priate distribution and utilization of ESRD care facil-
ities. To avoid duplication of effort and conflict of 
interest, working agreements are being developed be-
tween the networks and other agencies with similar 
objectives including Professional Standards Review 
Organizations (PSRO) and Health Systems Agencies 
(HSA). 
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Fig 1-ESRD networks as designated by the Department of Health, Education and Welfare. Most of Virginia is in Network 30. 
Each network is required to have a Medical Re-
view Board (MRB) to supervise the appropriateness 
and quality of care of ESRD patients. The Medical 
Review Board is appointed by the NCC and consists 
of a nephrologist, transplant surgeon, registered 
nurse, social worker, and three additional physicians. 
Standards of care are recommended by the MRB for 
approval by the NCC. It is expected that this proce-
dure will allow the establishment of high standards of 
care acceptable to all health care providers. Com-
pliance is voluntary and the NCC has no powers of 
enforcement. The Network 30 MRB is completing 
the first medical audit of dialysis patients, and an 
ongoing review program is planned that will consider 
all aspects of ESRD patient care. 
The distribution and utilization of medical care 
facilities have recently been the subjects of consid-
erable discussion and government attention at all 
levels; the ESRD program is no exception. The au-
thorizing legislation requires the establishment of 
minimal utilization rates of both dialysis and trans-
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Fig 2-Dialysis and transplantation activity in Virginia. Accurate 
dialysis data not available for 1972, 1974, and 1976. 
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ANNUAL PROJECTED COSTS OF MEDICAL SERVICES* 
MEDICARE DIALYSIS AND TRANSPLANT PATIENTS 
UNITED STATES, 1974-1984 ** 
Cost in Million Dollars 
1984 2,292 
1983 2,044 l 
1982 1,808 l 
1981 1,580 I 
1980 1,362 I 
1979 1, 153 I 
1978 952 l 
1977 759 l 
1976 572 I 
1975 408 I 
1974 243 l 
*Projections are based only on those inpatient and outpatient services covered by Medicare 
as of December 1977. 
**Calendar year. 
Fig 3-Projected costs of the ESRD program. Estimates provided by the Health Care Fina ncing Administrati o n, Office of Financia l and 
Actuarial A nalysis- Medicare. 
plant facilities. These rates have now been established 
and all facilities must be in compliance to receive 
payment for services. The NCC has no authority to 
regulate utilization or distribution of facilities, but it 
is expected that it will provide consultation to HSAs 
and state health departments in these matters. 
A national End-Stage Renal Disease M edica l 
Information System (ESRD MIS) is being developed 
to collect data on the types of facilities a nd services 
provided and on the course of illness of patients with 
ESRD. It is anticipated that the data generated will 
provide basic in formation to assess and evaluate the 
quality of care provided to ES RD patients and the 
type of information needed for effective health care 
delivery planning. This system replaced the Human 
Renal Transplant Registry and the National Dia lysis 
I 
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Registry. Unfortunately, this new system has been 
slow in starting and only limited data regarding 
ESRD patients have been published since the other 
registries ceased operation in 1976. 
As expected, the number of patients receiving 
ESRD care has rapidly increased since 1972. Accord-
ing to the National Dialysis Registry, there were only 
2,426 patients receiving dialysis in the United States 
in 1970.3 By June 1977 the Social Security Adminis-
tration estimated that 33,371 persons were receiving 
dialysis treatment in over 800 facilities under the 
ESRD programs.2 Transplantation activity has in-
creased also but not quite so rapidly.• The growth of 
dialysis and transplant activity in Virginia has gener-
ally paralleled that of the nation (Fig 2).5 There are 
approximately 27 dialysis facilities and 4 transplant 
programs [University of Virginia, Medical College of 
Virginia, VA Hospital (Richmond), Eastern Virginia 
Medical School] in this state. The basic needs of the 
patient population are being met. There remain , how-
ever, some areas where the distance to a facility is 
unacceptably long. This is particularly true in the 
south central and southwestern portions of the state, 
but it is expected that units will soon be organized in 
these poorly covered areas. Considerable effort is 
being made to increase transplant activity, particu-
larly by improving cadaver organ procurement. 
The ultimate size of the ESRD program is diffi-
cult to predict. It has been estimated that 50-75 new 
ESRD patients per million population per year will 
be candidates for treatment. This may well be a low 
estimate, since practically all patients are now consid-
ered candidates for some form of treatment. The 
Social Security Administration predicts 55,900 pa-
tients will be receiving treatment by 1982.2 
The cost of this program is staggering. Accord-
ing to the most recent projections, expenditures for 
1978 will approach $1.0 billion and will be $3.0 bil-
lion annually by 1984 (Fig 3).2 The cost of maintain-
ing a chronic dialysis patient who receives dialysis in 
a center approaches $25,000 per year. A saving of 
$8,000 to $10,000 annually is realized if the same 
patient performs self-dialysis at home. The cost of a 
successful transplant is approximately $25,000 the 
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first year and $1,000 to $3,000 each year thereafter. 6 
It is very likely that legislation will be passed in 1978 
that will provide incentives for both health care pro-
viders and consumers to employ the less expensive 
alternatives. Changes in reimbursement procedures 
are also expected. These measures will help, but im-
portant changes in the artificial kidney and consid-
erable improvement in transplant results will be re-
quired before major cost reductions are possible. 
In summary, a national health insurance pro-
gram for people with permanent failure of one organ 
system is well established. Appropriate care for most 
Americans with ESRD is readily available and 
affordable. The program, though effective and grow-
ing rapidly, is extremely expensive and cost contain-
ment is the major concern of health care providers 
and the government. The mechanism of administra-
tion of this program may well be the model for future 
national health insurance programs. 
Figures l and 3 are reproduced by permission from the US 
Department of Health , Education and Welfare. 
Figure 2 is abstracted from The Renal Program of Virginia 
1977. 
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Diabetic Nephropathy 
BARRY B. KIRSCHBAUM, M .D. 
Associate Professor of Medicine, Division of N ephrology, Medical College of Virginia, Health Sciences Division 
of Virginia Commonwealth University, Richmond, Virginia 
Any discussion of morbid events in diabetes is 
going to emphasize cardiovascular and peripheral 
vascular problems. Renal disease accounts for a rela-
tively small percentage of the mortality in diabetes; 
yet the overall incidence of diabetes mellitus in the 
population so greatly exceeds that of the various 
types of glomerulonephritis that it has become one of 
the most common causes of end-stage renal failure in 
this country. It is difficult to assign exact numbers 
because the figures in the medical literature vary con-
siderably; however, it is estimated that in the United 
States today there are some I 0 million people who are 
known to be diabetic, who would be found to be 
diabetic if tested, or who during the course of their 
lives will develop overt diabetes. In autopsy series of 
diabetics the prevalence of glomerulosclerosis has 
varied from 15% to 82%, with a mean of approxi-
mately 30%. This figure will vary depending on how 
carefully the kidneys are studied, particularly with 
respect to the use of special stains for identifying 
glomerulosclerosis; the incidence will also increase 
with the proportion ofjuvenile to adult onset diabet-
ics included in the sample. Renal failure is listed as 
the cause of death of 6% to 12% of diabetics, and its 
incidence is increased seventeenfold in the diabetic 
population as compared to the nondiabetic. These 
figures are probably applicable to those diabetics who 
have many complications and who require referral to 
major medical centers for treatment. In terms of the 
general diabetic population renal failure is probably 
in the range of 1 % to 2%. This means that the preva-
lence of glomerulosclerosis is severalfold higher than 
Correspondence and reprint requests to Dr. Barry B. Kirsch-
baum , Division of Nephrology, Box 197, Medical College of Vir-
ginia, Richmond, VA 23298. 
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the prevalence of renal failure, and that simply find-
ing the lesion on biopsy does not indicate that kidney 
function itself has been impaired or that there will be 
any abnormalities present on urinalysis. As a cause of 
end-stage renal failure, diabetes now accounts for 
some 15% to 25% of all new cases. 
Five years' survival after onset of proteinuria in 
diabetics compared to age-matched controls is 65% 
opposed to 73% for diabetics who do not develop 
proteinuria and 83% for non-diabetics. This does not 
mean that these people are dying of renal disease but 
that proteinuria heralds increased mortality from all 
causes. For juvenile diabetics it is extremely unusual 
for proteinuria to develop before 10 years' duration 
of the disease or to appear after a protein-free inter-
val greater than 30 years. This means that there are 
essentially two populations of juvenile diabetics with 
regard to the kidney; those who will have their dis-
ease for an unlimited amount of time and never de-
velop renal complications, and those who during the 
period between 10 and 30 years will note the onset of 
renal problems. Finally, in juvenile diabetes mellitus, 
azotemia defined as BUN in excess of 30 mg percent 
implies end-stage renal failure within three years. An 
important point to note is the rarity of a decline in the 
glomerular filtration rate before the onset of protein-
uria when the cause is diabetic nephropathy. Once 
renal failure does ensue it has been calculated that the 
glomerular filtration rate falls at an average rate of 1 
ml/min each month. With other forms of renal dis-
ease, hypertension greatly accelerates the rate of de-
cline in the glomerular filtration rate, an important 
point in treatment. 
Diabetic nephropathy and microangiopathy are 
the main topics under discussion here, but there are 
. several other factors which contribute in varying de-
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gree to the progression of renal failure in diabetics. 
As there is no therapy for diabetic nephropathy itself, 
these other factors assume an importance in line with 
their response to treatment. Infection, in particular 
pyelonephritis and papillary necrosis, becomes an ex-
tremely important factor in the management of the 
diabetic. This is true because the autonomic neuropa-
thy that may complicate diabetes favors development 
of a neurogenic bladder with high residual urine 
which may lead to reflux up the ureter, if the urine is 
infected, this reflux will result in secondary pyelone-
phritis and subsequent papillary necrosis with rapid 
loss of renal function . In patients who already have 
some type of renal failure, infection, even without 
involvement of the renal parenchyma, can result in a 
further decline in renal function. One of the theories 
that has been advocated to explain this is that certain 
types of bacteria can attach themselves to the cells of 
the ureter and thereby compromise the peristaltic 
action of the ureter which is important in propelling 
urine from the renal pelvis into the bladder. This 
results in a type of functional obstruction which acts 
in the same way as a true obstruction. Treatment of 
these patients with antibiotics to eradicate the bacte-
riuria improves ureteral peristalsis and renal function 
as well. 
Diabetes is also frequently complicated by hy-
perlipidemia and hyperuricemia. Uric acid crystals 
are a cause of interstitial nephritis, and high uric acid 
levels which lead to increased uric acid excretion can 
set the stage for uric acid calculi, obstruction, and 
subsequent infection. In the evaluation of a diabetic 
patient, the potential adverse effect of uric acid 
should be considered as this cause of renal failure is 
subject to therapy either by alkalinization of the urine 
or the use of allopurinol. 
A number of cardiovascular problems will also 
contribute to the declining glomerular filtration rate. 
Hypertension has already been mentioned; this can 
accelerate the vascular degenerative changes in the 
kidney, leading to nephrosclerosis which in turn can 
accelerate the hypertension, creating a cycle which 
may be interrupted if the hypertension is successfully 
controlled through the careful use of antihypertensive 
medication. Another complication of hypertension is 
its deleterious effect on the myocardium, leading to 
hypertensive cardiomyopathy and congestive heart 
failure. This will have an adverse effect on renal func-
tion, for as the kidney is damaged secondary to dia-
betes or other processes and as the vascular disease in 
the kidney progresses, autoregulation of blood flow 
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in the face of a reduced cardiac output is com-
promised; thw; low-output congestive heart failure 
will result in prerenal azotemia superimposed on the 
preexisting ren.il failure. In general, this situation is 
handled by the combination of digitalization and di-
uretics; however, it is worth pointing out the prob-
lems associated with excessive use of diuretics in these 
patients. They may get too dehydrated, a factor that 
will superimpose a prerenal type of azotemia upon 
their already preexisting level of renal failure. A com-
promise has to be worked out in terms of controlling 
the symptoms of congestive heart failure without, at 
the same time, contributing further to the impairment 
of renal function. Diabetics are prone to develop 
atherosclerosis, and particularly those patients who 
have extremely severe atheromatous disease of the 
aorta are subject to embolization to the renal vessels. 
This can present as episodic elevations of blood pres-
sure associated with fluctuations in the level of renal 
function reflected by BUN and creatinine and accom-
panied by microscopic or even gross hematuria, de-
pending on how much of the kidney is damaged or 
destroyed by infarction. 
The actual role of platelets in renal disease is still 
largely uncertain, although there is strong circum-
stantial evidence that platelets may be an important 
factor in the decline in renal function not only in 
diabetes but in glomerulonephritis as well. However, 
the abnormal properties of platelets in diabetes in-
crease the level of suspicion that they have a major 
role in the pathogenesis of the renal disease.' In the 
laboratory, platelets are studied by incubating them 
with various agents such as adenosine diphosphate, 
epinephrine, and collagen, which induce aggregation. 
The Table shows that the percent aggregation of 
platelets in diabetics to all three aggregating agents 
exceeds the control sample; moreover, platelets from 
diabetics aggregate at a lower concentration of these 
agents than the control sample. The reason for this is 
not exactly clear, but there is current evidence for a 
disturbance of prostaglandin synthesis by the plate-
lets of diabetics. The Figure shows the synthesis of 
immunoreactive prostaglandin E following the addi-
tion of a precursor of prostaglandin synthesis, arachi-
donic acid. Diabetic platelets show enhancement of 
prostaglandin formation following addition of the 
precursor. Thus with the evidence that platelets are 
more sticky in the diabetic and aggregate more easily, 
the possibility has been raised that within the micro-
circulation of the kidney, platelet aggregation occurs 
and leads to occlusion of the small blood vessels, 
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TABLE 
Percent Aggregation Four Minutes After the Addition of Each of 
the Aggregating Agents 
AGGREGATION(%) 
AGGREGATING DIABETIC 
AGENT CONTROLS SUBJECTS P VALUE* 
ADP: 
lµM 22 ± 7t 80 ± 4 (9):j: < 0.001 
2µM 69 ± 4 88 ± 4(9) < 0.005 
5µM 76 ± 4 
Epinephrine: 
86 ± 3 (9) NS§ 
lµM 39 ± 8 82 ± 5 (10) < 0.001 
2µM 60 ± 6 85 ± 3(9) < 0.01 
5µM 66 ± 6 84 ± 2(10) < 0.005 
Collagen: 
1 µg/ ml 53 ± 10 80 ± 3 (8) <0.05 
2µg/ ml 69 ± 8 84 ± 4 (8) NS 
lOµg/ ml 77 ± 8 86±3(8) <0.05 
* Difference between % aggregation seen in the platelet-rich 
plasma obtained from control and that in diabetic subjects. 
t Mean± SEM. 
:j: Figures in parentheses denote no. of subjects 
§ Not significant. 
resulting in glomerular ischemia and glomeruloscle-
rosis. There is some further evidence that involves 
platelets: thromboglobulin, a protein which is derived 
from the platelet, has been found to be increased in 
the circulation of those diabetics who have micro-
angiopathy. There are also tests for the presence of 
circulating platelet aggregates, and those diabetics 
who have the most severe small vessel disease are also 
the ones who show the highest levels of these circulat-
ing platelet aggregates. A recent study2 reported on 
the efficacy of sulfinpyrazone in the prevention of 
morbid events in patients who have severe coronary 
artery disease. There are active studies in progress to 
evaluate antiplatelet drugs in a variety of diseases 
that affect blood vessels, particularly coronary artery 
disease, atherosclerosis, and different types of renal 
disease. 
Amyloidosis is always listed as associated with 
diabetes mellitus. Certainly the onset of nephrotic 
syndrome or heavy proteinuria in a patient with long-
standing diabetes does raise the possibility that sec-
ondary amyloidosis may be present. With respect to 
immunologic factors which crop up in consideration 
of almost every type of renal disease, immuno-
globulins and complements are found within the 
glomerulus of the diabetic kidney. Their presence in a 
rather nonspecific pattern together with several other 
serum proteins has been interpreted not to represent 
a specific immunologic event such as immune com-
plex disease or anti-glomerular basement membrane 
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(anti-GBM) disease. Still, there are some lines of 
evidence which do not exclude completely the idea 
that immunologic problems are present in the dia-
betic and may be contributing to the renal disease. It 
was recently reported that juvenile .diabetes mellitus 
can be viewed as a genetic disease transmitted as an 
autosomal recessive gene.3 More interesting, perhaps, 
is the close association of the diabetic gene with the 
HL-A locus. This area of the chromosome is con-
cerned with a variety of immunologic responses, and 
many other diseases which have a close association 
with the HL-A locus have been more firmly estab-
lished as being the result of an immunologic abnor-
mality. Based on this there is still speculation that the 
diabetic may have altered immunologic responses 
and that this in turn may lead to primary or second-
ary renal damage. 
Drug-induced disease of the kidney, while not con-
fined to the diabetic, may assume increased signficance 
for these patients. There have been several reports of 
acute renal failure following the use of iodine con-
trast agents; for the most part, this can be prevented 
in the nondiabetic population by avoiding dehy-
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dration which is part of the preparation of patients 
for radiologic examinations. Diabetics, however, 
tend to develop acute renal failure with a greater 
frequency than nondiabetics; moreover, avoiding de-
hydration does not seem to be protective. This sug-
gests that something about the diabetic kidney pre-
disposes it to damage in the face of a quantity of 
hyperosomotic material. The question arises whether 
the diabetic kidney is more susceptible to other neph-
rotoxic agents such as the aminoglycoside antibiotics 
and a host of other medications which have potential 
nephrotoxicity. The lack of a definite answer suggests 
that in the management of diabetics both diagnostic 
and therapeutic agents should be selected for their 
reduced incidence of nephrotoxicity. 
Several studies have attempted to identify fac-
tors of importance in determining the development 
and progression of diabetic nephropathy. The data to 
be presented were derived from a small number of 
patients with biopsy-proven glomerulosclerosis who 
were followed for several years at which time a repeat 
biopsy was performed.' As far as the type of diabetes 
is concerned, of the 11 adult onset diabetics, 9 
showed no progression of their glomerulosclerosis, 
and 2 became worse. In contrast, of the 6 juvenile 
diabetics, l showed no change and 5 showed progres-
sion of the disease. With regard to blood glucose 
control, 6 of the patients maintained good sugar con-
trol for the whole length of the study and none of the 
6 showed progression of their glomerulosclerosis. By 
contrast, 13 patients were rated to be poorly con-
trolled and IO of them showed a progression of their 
renal lesions. In respect to the age of onset of these 
diabetics, patients in the group that showed no 
change were considerably older at the time of the 
onset of their diabetes than were those in the group 
that became worse. Obviously these three variables 
are not independent since, by and large, in older 
patients the adult onset type of diabetes can easily be 
managed by diet and weight reduction. But the re-
sults do suggest that blood glucose control may be 
important in terms of slowing down or averting the 
development of glomerulosclerosis. 
There appear then to be at least three phases in 
the renal disease that accompanies diabetes . The first 
is a pre-proteinuria phase. Phase 2 is marked by the 
onset of proteinuria, and phase 3 would be develop-
ment of azotemia. Several groups have tried to study 
the question, Is there anything abnormal about the 
kidney in the pre-proteinuric phase?, that is, before 
proteinuria becomes manifest and at a time when the 
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other renal function tests are also normal.6 If glo-
merulosclerosis progresses slowly with time, there 
might be a gradual increase in the excretion of albu-
min in the urine as the function of the duration of the 
diabetic process until such time as the amount of 
albumin in the urine definitely reaches an abnormal 
quantity. In a study of 97 young male diabetics who 
were followed from 1-19 or more years after the 
diagnosis of diabetes, there was no increase in albu-
min excretion throughout this period of time. Those 
who develop proteinuria are clearly distinguished 
from those who do not. Because strenuous exercise 
increases albumin excretion, a group of 13 juvenile 
diabetics were exercised at a rate which had not af-
fected urinary albumin levels in 9 normal controls. 
The diabetics showed a statistically significant in-
crease in protein excretion that returned to baseline 
after stopping the exercise. Another element that has 
been examined is the excretion of low molecular 
weight proteins by diabetics; these represent proteins 
that are considerably smaller than albumin and are 
freely filtered at the glomerulus. Almost none, how-
ever, appear in the urine because most of these fil-
tered proteins are reabsorbed by the cells of the prox-
imal tubule . In the pre-proteinuric phase, diabetics 
show an increase in excretion of low molecular 
weight proteins. These results, together with addi-
tional information on albumin excretion, suggest that 
the metabolic state of diabetes can adversely affect 
renal cell function so that when the diabetic is poorly 
controlled, the cells are less able to reabsorb filtered 
proteins, including albumin. 
In addition to studies on patients, there have 
been attempts to gain information about diabetes 
through the use of animal models. Diabetes may be 
induced in animals either by removing the pancreas 
or by destroying the insulin-producing cells with a 
chemical such as streptozotocin. These animals then 
develop hyperglycemia and over the next several 
months their kidneys will show the kind of lesions 
that are present in humans: namely, there is an in-
crease in the mesangial matrix and an increase in the 
degree of glomerulosclerosis together with deposition 
of immunoglobulins and complement. If the kidneys 
from a diabetic animal are transplanted into a normal 
animal, the diabetic changes rapidly disappear. On 
the other hand, if kidneys from a normal animal are 
transplanted into a diabetic animal, diabetic changes 
will develop. When pancreatic tissue is successfully 
transplanted into the diabetic animal, then coincident 
with the rise in insulin level, there is striking improve-
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ment in the appearance of the diabetic kidney. This 
indicates that the changes seen in the glomerulus are 
at least initially reversible and that metabolic control 
of blood glucose, or at least the presence of insulin in 
appropriate quantities to keep the blood glucose nor-
mal, is a contributing factor to the development of 
diabetic changes. 
The outline for therapy of diabetic kidney dis-
ease calls for the best blood glucose control circum-
stances will permit. Antihypertensive therapy has to 
be emphasized together with optimal management of 
congestive cardiac failure in order to maintain a high 
cardiac output and avoid prerenal azotemia. The pa-
tient should be evaluated for obstruction and for 
urinary tract infection. Nephrotoxic agents should be 
avoided as much as possible. As for vascular compli-
cations, anticoagulation offers little value as, by and 
large, patients who have renal disease also have reti-
nal disease which is aggravated by these drugs. The 
antiplatelet drugs, based on available evidence, are 
quite promising, although unproven at the present 
time. As far as the treatment of end-stage renal dis-
ease in the diabetic is concerned, the same four mo-
dalities are open to these patients as anyone else: 
living related transplants, cadaver transplants, hemo-
dialysis and peritoneal dialysis . Because of technical 
advances, greater experience in dealing with diabet-
ics, and earlier acceptance of diabetics into end-stage 
renal failure programs, the prognosis has improved 
considerably during the past couple of years.6 Trans-
plantation from a living related donor seems to be as 
good in diabetics as in the general population, so that 
this would seem to be the treatment of choice for a 
diabetic with end-stage renal disease. The results with 
cadaver kidney transplantation tend to be poorer 
than those of the general population and until we 
have some better methods of managing cadaver kid-
ney transplants in general, this is probably the least 
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promising mode of therapy for the diabetic. Hemo-
dialysis is the treatment that will be applied to the 
majority of these people. The problems are in estab-
lishing a suitable blood access site because of severe 
vascular disease and the requirement for anti-
coagulation during dialysis which frequently leads to 
a deterioration of vision. Many nephrologists now 
feel that the treatment of choice if a living related 
donor is not available is peritoneal dialysis; the major 
problem here is peritonitis as well as the necessity for 
using high-glucose containing solutions in the perito-
neal cavity which can lead to severe degrees of hyper-
glycemia, but the complications associated with 
bleeding in the eye are avoided and vascular access is 
not necessary. 
The table and the figure are reproduced with permission from 
the New England Journal of Medicine (297: 1306-1310, 1977). 
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GEORGE E. SCHREINER, M.D. 
Pyelonephritis 
WILLIAM F. FALLS, JR ., M .D. 
Evaluation of an Abnormal Urinalysis in the Asymptomatic Patient 
DOUGLAS M. LANDWEHR, M.D. 
Treatment of End-Stage Renal Disease 
WILLIAM K. STACY , M.D . 
Diabetic Nephropathy 
BARRY 8 . KIRSCHBAUM, M .D . 
Correction Notice: On p. 66 of the MCY / Q, 14:2, 1978, Management of Urological 
Problems in Primary Care, the second sentence in the footnote should have read, 
"An acceptable substitute is Protargol Urethral suppositories ( 1 % ) which can be 
made-to-order in pharmacies ." 
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PROCEEDINGS OF THE 50TH ANNUAL M c GUIRE L ECTURE SERI ES 
SPONSORED BY THE DIVISION OF CARDIOVASCULAR DISEASE AND THE 
D EPARTMENT OF CONTINUING MEDICAL EDUCATION 
Single copy $3.00 
when 
stress · 
makes 
wa 
spasm 
reactoe .. 
·~ 
, K ymograph1c record 
obtained from sigmoid 
colon of a patient with 
imt.able bowel syndrome 
dunng stress·provoking 
interview. Adapted from 
Almy et al. 
A normal reaction to emotional stress is a marked 
increase in both the strength and frequency of wave-like 
contractions of colonic motility.1 However, in the patient 
with irritable bowel syndrome, this psychovisceral 
reaction is of greater intensity and duration than normal.2 
The result can be G.I. spasm. 
When spasm and pain associated with irritable bowel 
syndrome call for treatment beyond your counseling and 
reassurance, Donnatal may prove to be a helpful adjunct. 
The smooth central sedation and prompt peripheral 
antispasmodic/ anticholinergic action of Don natal may 
provide this symptomatic relief necessary to help calm 
the waves ... and quell the spasm. 
References: 1. Almy, TP, Kern, F, and Tulin, M.: Alterations in colonic function in 
man under stress. II : Experimental production of sigmoid spasm in healthy persons. 
Gastroenterology 12(3):425-436, 1949. 2. Almy, TP, Hinkle, L.E., Berle, B., et al. : 
Alterations in colonic function in man under stress. Ill: Experimental production of 
sigmoid spasm in patients with spastic constipation. Gastroenterology 
12(3):437-449, 1949. 
''' Indications: Based on a review of this drug by the NAS/ NRC and / or 
other information, FDA has classified the following indications as 
possibly effective: adjunctive therapy in the treatment of peptic ulcer; 
the treatment of the irritable bowel syndrome (irritable colon, spastic 
colon, mucous colitis) and acute enterocolitis. 
Final classification of the less-than-effective indications requires 
further investigation. 
Contraindicated in patients with glaucoma, renal or hepatic 
disease, obstructive uropathy (for example, bladder neck obstruction 
due to prostatic hypertrophy), or a hypersensitivity to any of the 
ingredients. Blurred vision, dry mouth, difficult urination, and flushing or 
dryness of the skin may occur at higher dosage levels, rarely at the 
usual dosage. 
Onnalal® Ph(~~~~~~ital may be habit forming) Hyoscyamine sulfate 
~~~~~~nee s~~:~bromide 
the spasm relaxer 
A·H·ROBINSA.H. Robins Company, Richmond, Virginia 23220 
'<..L...J 
each tablet, capsule each 
or 5 ml (tsp) of elixir Donnatal 
(23% of alcohol) No. 2 Tablet 
('!. gr) (Y2 gr) 
16.2 mg 32.4 mg 
0.1037mg 
0.0194 mg 
0.0065 mg 
0.1037 mg 
0.0194 mg 
0.0065 mg 

